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ABSTRACT 
 
Huntington Disease (HD) is a neurodegenerative disorder that is inherited in an autosomal 
dominant manner, and for which testing is available. The aim of this retrospective file-based study 
was to analyse the numbers and demographics of individuals who had diagnostic, predictive or 
prenatal genetic counselling and/or testing for HD between January 1998 and December 2006 
through the Division of Human Genetics, National Health Laboratory Service and University of 
the Witwatersrand, Johannesburg.   
 
Files for 287 individuals who had genetic counselling and/or testing for HD were included in this 
study, with 77% being diagnostic cases, 20% predictive and 3% prenatal. When the results 
obtained in this study were compared to a study by Kromberg et al. (1999) done previously in the 
same Division, it was found that there has been an increase in the number of diagnostic and 
predictive tests done per year during this study, with diagnostic tests making up a greater 
percentage of the total number of tests performed.  
 
One of the objectives of this study was to characterise the individuals who requested HD testing 
and to compare the characteristics of those in the diagnostic testing group to those in the predictive 
testing group. The median age of the individuals in the predictive testing group was 30 years, 
which was significantly different from the median age of 49 years for individuals in the diagnostic 
testing group (p<0.001). It was found that there were significantly more women than men 
requesting predictive testing (p=0.02), while the number of males and females in the diagnostic 
testing group was similar (p=1.00). There was also a greater percentage of employed (76.4%) 
versus unemployed (23.6%) individuals in the predictive testing group, while the percentages of 
employed and unemployed individuals in the diagnostic testing group were similar (45.5% and 
54.5% respectively). Significantly more individuals in the diagnostic testing group had children 
(74.5%) compared to those in the predictive testing group, where 44.6% of individuals had one or 
more children. There was a greater percentage of white individuals in the predictive testing group 
(91% white; 3.5% black) compared to the diagnostic testing group (48% white, 42% black). 
 
The completion rate of the predictive testing process was 66.7%. In the predictive testing group, 
39.5% of individuals tested positive for HD, and in the diagnostic testing group 53% of individuals 
 v
tested positive for HD. Nine prenatal tests were requested by five different couples, and 7 tests 
were performed. Three of these fetuses tested positive for HD (including a set of twins) and these 
two pregnancies were terminated. 
 
Overall, there seems to be a lack of awareness of and/or access to the genetic services offered for 
HD through the Division of Human Genetics, National Health Laboratory Service and University 
of the Witwatersrand, Johannesburg, particularly among black individuals and the professionals 
treating them. Information generated from this study can be used to understand the individuals 
seeking genetic counselling and/or testing for HD better, and can direct efforts to improve 
awareness and access amongst groups noted to be under-represented. It also serves as a starting 
point for further research.   
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1 INTRODUCTION 
 
 
Huntington disease (HD) is a neurodegenerative disorder that is inherited in an autosomal 
dominant manner (Purdon, Mohr, Ilivitsky et al. 1994). Symptoms of HD include progressive 
dementia, cognitive dysfunction, psychiatric problems and choreiform movements. It is estimated 
that the worldwide prevalence of HD is about 4 to 8 per 100,000 but varies considerable (from 0.5 
to 10 per 100,000) in different population groups (Harper 1996, Rimoin, Connor, Pyeritz et al. 
2002; Landles and Bates 2004). The disease seems to be less common in the Japanese, Chinese, 
and Finnish populations and in African black populations, but much more common in individuals 
of European descent (Harper, 1996; Rimoin et al. 2002). HD is caused by the presence of an 
expanded number of CAG repeats in the important transcript 15 (IT15) gene on chromosome four 
(Huntington's Disease Collaborative Research Group 1993), but a second disease-causing allele 
has been found in black African patients (Holmes, O'Hearn, Rosenblatt et al. 2001). This is also an 
expansion mutation which leads to HD-like symptoms, but it occurs in the Junctophilin 3 (JPH3) 
gene and involves a CAG/CTG repeat expansion (Holmes et al. 2001). 
 
Testing is currently offered in South Africa to detect repeat expansions in these two genes. It can 
be used for diagnostic testing when individuals are symptomatic, predictive testing for at-risk 
individuals, or prenatal testing. Genetic counselling is also offered to both at-risk and affected 
individuals and their families for HD predictive, diagnostic or prenatal testing. 
 
The purpose of this study was to assess the number of patients seen for genetic counselling and/or 
genetic testing for HD in the Division of Human Genetics, National Health Laboratory Services 
and University of the Witwatersrand, Johannesburg (here forth referred to as the Division) between 
January 1998 and December 2006. This study also characterised these patients by obtaining 
demographic information about them, their motivations for testing and test results. This may give 
genetic counsellors and clinicians within the Division further insight into their patients and their 
needs. It is hoped that such information will be useful in the provision of both clinical and 
laboratory services and will allow appropriate services to be provided. 
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1.1 CLINICAL FEATURES OF HUNTINGTON DISEASE 
 
The age of onset of this disorder is usually in the third or fourth decade of life, but can present in 
early childhood or as late as in the eighties (Young 2003; Landles and Bates 2004). The symptoms 
of HD are progressive and once an individual starts showing symptoms, their survival time is 
generally not more than 20 years (Purdon et al. 1994).  
 
1.1.1 Neurological symptoms of HD 
 
Neurological symptoms are often the first presentation of HD (Harper 1996). Early 
motor/neurological signs of HD include restlessness, hyper-reflexia, abnormal eye movements and 
rapid and inappropriate movement of the fingers, hands or toes (Rimoin et al. 2002). Abnormal eye 
movements include a decreased ability to initiate small, rapid, jerky movements of the eyes 
(saccades) when trying to focus on objects, such as while turning the head or moving, as well as 
increased blinking (Harper 1996). Dysarthria is also common in early HD. Dysarthria is the 
disturbance of speech, such as the rhythm of speaking as well as the speed, and may later cause 
speech to be unintelligible (Harper 1996). 
 
Later neurological symptoms include choreiform movements which are involuntary movements 
such as jerking or writhing that may affect the limbs and the face, and lead to difficulties talking 
and swallowing (Purdon et al. 1994). This chorea is continuously present while the individual is 
awake and tends to worsen during times of stress (Rimoin et al. 2002). The chorea associated with 
HD is variable, but always includes some degree of dystonia which causes sustained contractions 
of muscles leading to twisting movements, abnormal posture and slow abnormal movements 
(Harper 1996; Rimoin et al. 2002). As the disease advances, other symptoms such as rigidity and 
loss of voluntary movements as well as the dystonia, become more apparent (Harper 1996; Rimoin 
et al. 2002). Difficulties in swallowing may also become more obvious and this increases the risk 
of asphyxiation (Harper 1996). Weight loss is common in the later stages of HD, as is incontinence 
(Harper 1996). 
 
Other neurological abnormalities may include epilepsy and cerebellar dysfunction, but these are 
less common in the adult onset form of HD, compared to the juvenile form of HD. HD can also 
Introduction 
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lead to changes in gait. The gait of an individual with HD, especially one who has had chorea for 
many years, tends to be wide-based and staggering (Harper 1996). Some individuals may have a 
slow, unsteady gait due to bradykinesia and are more likely to fall (Harper 1996). 
 
1.1.2 Cognitive symptoms of HD 
 
Cognitive symptoms associated with HD include progressive dementia and cognitive dysfunction 
such as memory loss, a decreased ability to learn new material, and attention and concentration 
problems (Purdon et al. 1994; Harper 1996; Young 2003). Language difficulties are common in 
HD and can affect both the ability to speak effectively and to understand others. Writing is also 
usually affected in individuals with HD, due to both neurological and cognitive difficulties (Harper 
1996). Individuals with HD may also experience a decline in visual perception (Purdon et al. 1994; 
Harper 1996; Young 2003). They may also have decreased problem-solving abilities and difficulty 
with concept formation (Harper 1996). The cognitive symptoms associated with HD may lead to 
problems with social interaction and inappropriate emotional responses (Harper 1996).  
 
The symptoms of HD result from the loss of striatal neurons (nerve cells located within the dorsal 
striatum) and atrophy of the caudate nucleus and the putamen in the brain (Rimoin et al. 2002). 
The caudate nucleus and putamen are located near the centre of the brain, forming the dorsal 
striatum, and are involved in learning and memory (Rimoin et al. 2002). 
 
1.1.3 Psychiatric symptoms of HD 
 
Psychiatric symptoms associated with HD are variable and can include irritability, depression and 
suicidal ideation (Purdon et al. 1994; Harper 1996; Young 2003). Less common psychiatric 
manifestations in HD can include paranoia and delusions, mania, personality disorder and 
schizophrenia (Harper 1996).  
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1.1.4 Features of HDL2 
 
Features of HDL2 are similar to those seen in patients with HD1. They include neurological 
symptoms such as dysarthria, hyper-reflexia, chorea, dystonia, rigidity and bradykinesia, as well as 
tremor (Margolis, Holmes, Rosenblatt et al. 2004). HDL2 also presents with the cognitive and 
psychiatric symptoms seen in HD1 (Margolis et al. 2004; Greenstein, Vonsattel, Margolis et al. 
2007). Individuals with HDL2, like individuals with HD1, experience progressive worsening of 
symptoms over a period of 10-20 years, but they tend to present later than individuals with HD1, 
usually only in the 4th decade (Margolis et al. 2004). 
 
1.1.5 Features of Juvenile HD 
 
HD that presents before the age of 20 years is termed “Juvenile HD” (Nance and Myers 2001). 
Symptoms in children and adolescents include severe mental deterioration, cerebellar 
abnormalities, abnormalities of eye movement, epilepsy, rigidity, ataxia, bradykinesia and general 
motor abnormalities (Teisberg 1995; Harper 1996; Nance and Myers 2001). They rarely present 
with chorea (Harper 1996). In South Africa, the prevalence of juvenile HD is about 4% in the 
white HD population, and as high as 15.7% in the mixed ancestry HD population (Hayden, 
MacGregor, Saffer et al. 1982), compared to 7-10% worldwide (Harper 1996). 
 
1.2 INHERITANCE OF HUNTINGTON DISEASE 
 
HD has an autosomal dominant inheritance pattern and therefore the child of an affected individual 
has a 50% chance of inheriting the expanded allele. Because this disease is usually completely 
penetrant, an individual who has inherited the gene will at some stage present with symptoms of 
this disorder (Purdon et al. 1994; Landles and Bates 2004).  
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1.3 THE GENETICS OF HUNTINGTON DISEASE 
 
1.3.1 Huntington Disease 1 
 
The HD1 gene, IT15, is located on chromosome 4p16.3. This gene is comprised of 67 exons, and is 
180kb in length. The resulting protein, called Huntingtin (htt), consists of 3144 amino acids and 
has a molecular mass of 348kDa. Htt has two forms – a 13.7kb transcript and a 10.3kb transcript 
(Warby, Graham and Hayden 2007). 
 
In unaffected individuals, the first exon of this gene contains between 9 and 35 CAG repeats, each 
of which codes for the amino acid glutamine (Huntington Disease Collaborative Research Group 
1993). This polyglutamine tract forms part of the htt protein that is located in the cytoplasm of 
many cells in the body, particularly in the neurons of the brain (Cattaneo, Rigamonti, Goffredo et 
al. 2001; Young 2003). HD is caused by an expansion in the number of CAG repeats in IT15 to 
more than 40 repeats (Huntington Disease Collaborative Research Group 1993). As the number of 
CAG repeats increases, so does the number of glutamine residues in the htt protein and this causes 
the protein to undergo a conformational change, forming mutant htt (Cattaneo et al. 2001; Landles 
and Bates 2004). Incomplete penetrance can occur when the number of CAG repeats is 36 to 39 
(Lopez 2007). The incomplete penetrance associated with this allele range means that it is 
uncertain whether or not an individual will present with symptoms. Some individuals with repeats 
in this range may present with many of the symptoms of HD, while others may have no symptoms 
at all or may have only mild symptoms, such as restlessness (Rubinsztein, Leggo, Coles et al. 
1996). There may also be genetic or environmental factors that could influence the development of 
HD in individuals with 36 to 39 repeats (Rubinsztein et al. 1996), making it difficult to provide 
these individuals with definitive answers regarding their HD status. It has been found that 
individuals with intermediate alleles (27 to 35 CAG repeats) are not at risk of developing HD 
themselves, but the repeat is unstable and can expand when passed from a parent to their child 
(Semake, Creighton, Warby et al. 2006; Lopez 2007). Various factors can influence the expansion 
of intermediate CAG repeats to the “incomplete penetrance” range. These include the length of the 
CAG repeat, with longer repeats being more likely to expand, as well as the gender and age of the 
parent carrying the intermediate allele, with the risk being greater when the allele is passed on 
from a father to his children, particularly if the father is of advanced paternal age (older than 35) 
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(Lopez 2007). It is therefore important to counsel the patient appropriately if repeat numbers in 
these ranges are found.  
 
1.3.2 Huntington Disease-like 2 
 
In a few individuals who present with clinical features of HD, an IT15 CAG repeat expansion is 
not detected (Stevanin, Fujigasaki, Lebre et al. 2003). In some of these patients, molecular studies 
have shown the presence of a CAG/CTG repeat expansion in another gene, JPH3, located on 
chromosome 16q24.3 (Holmes et al. 2001). This gene is 95.4 kb in length and consists of 5 exons 
(GenAtlas 2003). The JPH3 gene encodes a 748 amino-acid protein – junctophilin-3 (JHP3) – 
which has a molecular weight of 81kDa and is a component of junctional membrane complexes 
(Margolis 2006). 
  
Individuals with HDL2 have an expanded number of CAG/CTG repeats to more than 40 (Margolis 
2006). Normal allele ranges are 6 to 28 CAG/CTG repeats; reduced penetrance alleles, which may 
expand when passed on, range from 29-39, and more than 40 repeats results in fully penetrant 
HDL2 (Margolis 2006; Greenstein et al. 2007). This expanded CTG repeat is alternatively spliced, 
forming either poly-leucine or poly-alanine amino acid tracts in the junctophilin-3 protein or may 
be spliced out (Holmes et al. 2001). It is not understood how this causes HD-like symptoms 
(Margolis, Rudnicki and Holmes 2005).  
 
An expansion of the number of CAG/CTG repeats in JPH3 has not yet been detected in Caucasian 
populations, but occurs in individuals of African ancestry (Stevanin et al. 2003; Margolis et al. 
2005; Margolis 2006). Worldwide prevalence rates are not known, but it is thought to occur in only 
1% of patients with HD-like symptoms who test negative for HD1 (Margolis 2006). Although 
HDL2 is considered to be rare in many parts of the world, it is thought to occur in about one third 
of black South African HD patients (A. Krause, personal communication, November 2007).  
 
1.3.3 Juvenile HD 
 
There is a phenomenon that can occur in HD families, where the number of repeats expands when 
passed on to successive generations. This is termed “anticipation”, and in HD, this tends to occur 
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when a father passes on the disease gene to his children. The increased number of repeats in 
children of affected individuals often leads to the earlier-onset juvenile form of HD in these 
children (Nance and Myers 2001). Juvenile HD usually occurs when the number of repeats is 
greater than 60 (Teisberg 1995; Harper, Lim and Craufurd 2000; Nance and Myers 2001) 
 
1.4 THE PATHOGENESIS OF HUNTINGTON DISEASE 
 
1.4.1 Huntington Disease 1 
 
Mutant htt impacts on many cell processes, and the disruption of these processes is thought to 
induce the neurodegeneration seen in patients with HD1 (Cattaneo et al. 2001; Young 2003). 
Mutant htt disrupts the transportation of vesicles containing brain-derived neurotrophic factor 
(BDNF) in neurons and the transportation of organelles within cells (Gutekunst, Levey, Heilman et 
al. 1995; Gauthier, Charrin, Borrell-Pagès et al. 2004). Because the striatal neurons do not receive 
sufficient BDNF, a pro-survival factor that contributes to survival signals the cells receive, the 
cells become susceptible to cell death, which leads to neurodegeneration (Zuccato, Ciammola, 
Rigamonti et al. 2001; Gauthier et al. 2004; Borrell-Pages, Zala, Humbert et al. 2006) 
 
Mutant htt has been found, in mouse models, to disrupt the functioning of mitochondria, leading to 
calcium (Ca2+) dysregulation (Bezprozvanny and Hayden 2004). Excess calcium in the cytoplasm 
of cells, along with decreased amounts of BDNF, is thought to lead to the abnormal activation of 
proteases which cleave the mutant htt, resulting in the formation of N-terminal fragments 
containing the glutamine residues (termed polyQ stretches) (Hermel, Gafni, Propp et al. 2001; 
Gafni, Hermel, Young et al. 2004; Hermel, Hart, Gunduz et al. 2004; Borrell-Pages et al. 2006). 
These fragments are then transported into the nucleus, where they induce death of the spiny striatal 
neurons by interfering with transcription of various genes as well as interfering with intracellular 
transport (Luthi-Carter, Strand, Peters et al. 2000; Borrell-Pagès, Canals, Cordelières et al. 2006). 
These polyQ fragments also form aggregates which can be deposited in the cytoplasm (where they 
are termed cytoplasmic aggregates or inclusions), in the nucleus (intranuclear inclusions) or in 
striatal neurons (neuritic inclusions), and are commonly found in the cortex of the brain (Li H, Li 
SH, Johnston H et al. 2000; Cattaneo et al. 2001; Young 2003; Borrell-Pagès et al. 2006). These 
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aggregates have been shown to impair mitochondrial transport, which may be an important factor 
in the pathogenesis of HD1 (Chang, Rintoul, Pandipati et al. 2006). 
 
1.4.2 Huntington Disease-like 2 
 
Not much information is known about how the expanded CAG/CTG repeat in JPH3 causes HDL2.  
JPH3 is expressed primarily in the brain and is involved in forming a junctional complex between 
the cytoplasmic membrane and the endoplasmic reticulum and ion channels within the cells 
(Margolis 2006; Rudnicki, Holmes, Lin et al. 2007). In HDL2, RNA transcripts with expanded 
CUG repeats form foci in the frontal cortex, with portions of the transcript being incompletely 
processed (Rudnicki et al. 2007). These transcripts have been shown to be cytotoxic and may have 
the same pathogenesis as in HD1, which is one way in which expanded CAG/CTG repeats in 
HDL2 are thought to cause the HDL2 phenotype (Rudnicki et al. 2007). Another protein, MBNL1 
(muscleblind-like protein 1), which is involved in the regulation of splicing of transcripts, has been 
shown to co-localize with these RNA foci, resulting in there being less available MBNL1 within 
the cell (Rudnicki et al. 2007). It is thought that this may lead to missplicing of other genes, but 
more research is needed to confirm this (Margolis 2006; Rudnicki et al. 2007).  
 
Another possible mode of pathogenesis in HDL2 relates to the function of JPH3 within the cell. 
Alteration in the structure of JPH3 due to the expanded CAG/CTG repeats may interfere with these 
junctional complexes and lead to calcium dysregulation (Margolis 2006). The presence of the 
incompletely processed JPH3 transcripts leads to reduced expression of JPH3, which may also 
lead to disruption of its function and contribute to the disease pathogenesis (Rudnicki et al. 2007).  
 
1.5 MOLECULAR GENETIC TESTING FOR HUNTINGTON DISEASE 
 
Direct mutation testing has been available for HD1 testing since 1994. Samples collected in the 
Division, were initially sent to laboratories overseas (mainly in England and the Netherlands) and 
later to the Department of Human Genetics at the University of Cape Town (Kromberg, Krause, 
Spurdle et al. 1999). Since 2001 samples have been analyzed at the Division, using direct mutation 
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analysis. This involves using PCR primers to amplify the region where the CAG repeats are found 
to determine the exact number of repeats that are present in the gene. A result indicating more than 
40 repeats is considered positive for HD1.  
 
As the symptoms associated with HD1 are difficult to distinguish from HDL2 (Margolis et al. 
2005) the Division currently also offers all individuals of black or mixed ancestry diagnostic 
testing for HDL2. Samples have also been tested retrospectively. This testing has been available at 
the Division since 2004 and is done using direct mutation testing. The presence of an expanded 
number of CAG/CTG repeats (more than 40) is considered a positive result for HDL2.  
 
Before direct mutation testing became available, linkage analysis was done and is still available for 
rare cases when exclusion testing is requested. Linkage analysis involves the detection of markers 
that are known to flank the disease gene. These markers are usually single nucleotide 
polymorphisms (SNPs) or microsatellites that are near enough to the disease gene not to be subject 
to homologous recombination (Ball, Tyler and Harper 1994). If an individual is known to have HD 
it is possible to trace the markers that are linked to the disease gene through each generation in the 
family, and determine who is at risk of developing HD (Ball et al. 1994). Linkage analysis can 
only be used to modify an individual’s risk of developing HD and cannot determine with certainty 
whether or not the mutated gene is actually present in an individual (Ball et al. 1994). This is 
because there is a small possibility of recombination occurring between the gene and marker.  
 
1.5.1 Diagnostic Testing for HD 
 
Diagnostic testing is used for the purpose of confirming the diagnosis of HD in individuals who are 
symptomatic (Kromberg et al. 1999). Diagnostic testing for HD is currently done at the Division 
using direct mutation analysis. 
 
1.5.2 Predictive Testing for HD 
 
Asymptomatic, at-risk individuals may wish to know whether or not they have inherited HD from 
an affected parent. Since 1989, these individuals have been offered predictive (also termed pre-
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symptomatic) HD testing, which was done by linkage analysis up until 1994, and is now done by 
direct mutation testing. 
 
There is an internationally accepted protocol which is followed before an asymptomatic individual 
is tested for the presence of the expanded CAG repeat causing HD1 or for the CTG repeat causing 
HDL2. The protocol followed in the Division is based on the one which was developed by the UK 
Huntington Disease Association in 1991 (Crauford, Tyler and U.K. Huntington's Prediction 
Consortium 1992). For an individual to be eligible to enter the predictive testing program, they 
should meet the following criteria: 
 
1. They must have a confirmed family history of HD or one which is highly suggestive of the 
disease. It is important to have a confirmed (positive) HD result in an affected family 
member, if possible, to ensure that the disease being inherited and tested for in the family is 
actually HD (Kromberg et al. 1999).  
2. They should be at 25-50% risk of having inherited the mutated gene but an individual with 
a lower risk will not necessarily be excluded.  
3. They must be at least 18 years of age at the time of testing. Rarely, exceptions can be made 
in the case of mature minors.  
4. They must give informed consent. 
5. Individuals who request predictive testing, but are found to have a severe mental illness or 
who are at high risk of suicide are counselled against participating in the predictive testing 
program, but cannot be excluded.  
6. It is advisable that the individual undergoing testing has a support person who accompanies 
them to all the appointments, especially the result-giving session. This support person can 
be a spouse or friend, but should preferably not be someone who is themselves at risk of 
inheriting HD and who may wish to undergo predictive HD testing later. 
 
Individuals eligible for inclusion in the predictive testing program are required to undergo various 
assessments before they will be tested for the HD gene mutation. The first step in the predictive 
testing program involves one or more appointments with a genetic counsellor where a family 
history is obtained and where the individual’s understanding of HD, their motivation for 
undergoing testing and their thoughts regarding receiving a positive HD result and receiving a 
negative HD result are discussed (Kromberg et al. 1999). The predictive testing protocol is also 
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explained during one of the genetic counselling sessions. The individual is then referred to a 
neurologist, a psychologist and a psychiatrist who each interview and examine the individual using 
a variety of tests. This is to determine whether or not the individual has symptoms of HD, and if 
there is any reason for them to be discouraged from undergoing predictive HD testing (Crauford et 
al. 1992; Kromberg et al. 1999). If they are found to show symptoms of HD, then they are not 
required to complete the predictive testing protocol and diagnostic testing is offered instead. 
 
After the assessments, the individual returns to the genetic counsellor who will have been informed 
of the findings of the neurologist, psychiatrist and psychologist and can discuss with the individual 
whether they want to proceed with testing (Kromberg et al. 1999). If they do wish to proceed, 
blood will be taken for direct mutation analysis. When the results are available, the genetic 
counsellor will discuss the results with them at another appointment. After a result is given, the 
individual will be offered follow-up appointments, should they need them, with the genetic 
counsellor, psychologist, psychiatrist and/or neurologist (Kromberg et al. 1999).    
 
1.5.3 Prenatal Testing for HD 
 
Prenatal testing for HD is also available in South Africa. Prior to 1994 this was done using linkage 
analysis, but is now done using direct mutation testing or exclusion testing in rare cases. Prenatal 
testing can be requested on the fetus of an individual who is affected or at 50% risk of having 
inherited HD and termination of pregnancy can be offered when a fetus is found to have an 
expanded repeat or is found to be high risk by linkage analysis. 
 
1.6 GENETIC COUNSELLING FOR HD 
 
1.6.1 Genetic Counselling 
 
HD is an inherited disorder and individuals who have the disease or are at risk of developing it, 
should be offered genetic counselling. The most up-to-date definition of genetic counselling is that 
given by the National Society of Genetic Counselors (National Society of Genetic Counselors' 
Definition Task Force, Resta, Biesecker et al. 2006). They define genetic counselling as “the 
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process of helping people understand and adapt to the medical, psychological, and familial 
implications of the genetic contributions to disease” and includes “interpretation of family and 
medical histories”, education of patients about the disorder or condition (inheritance, risks, medical 
information, cause, treatments, prevention), as well as counselling patients to enable them to make 
informed choices regarding the condition (National Society of Genetic Counselors' Definition Task 
Force et al. 2006).  
 
1.6.2 Diagnostic HD testing issues   
 
A diagnostic test is done to confirm that the patient’s clinical features are caused by HD. Receiving 
a positive or negative result may have psychological consequences for both the individual and 
his/her family. A positive result helps to identify the cause of the symptoms but the individual 
testing positive for HD, and their family, has to come to terms with the progression of the disorder 
and understand that there is no cure. The family may also have to care for the affected individual 
and make decisions regarding both their future and that of the affected individual (Tibben 2007). 
Treatment and care of an individual with HD may also place a financial burden on the family, 
especially as symptoms progress and the affected individual can no longer work (Harper 1996). 
Another aspect of a positive test result which would impact on the family is that the individual’s 
children are at 50% risk of inheriting HD (Harper 1996; Tibben 2007). Many affected individuals 
may already have children when they start showing symptoms of HD, so reproductive decision-
making is no longer an option (Harper 1996).  
 
A negative test result for HD means that the patient’s symptoms are not caused by HD. The 
individual and their family may find it reassuring that the individual’s symptoms are not due to 
HD, but they may then have to deal with a different diagnosis, or with not finding a diagnosis. The 
risk to their children may also then be unknown.  
 
1.6.3 Predictive HD testing issues  
 
Individuals who are at risk of inheriting HD but are not currently showing symptoms suggestive of 
HD are termed “pre-symptomatic” and should receive genetic counselling. If they wish to know 
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their status, they need to go through a predictive testing protocol (discussed in section 1.5.2) 
(Chapman 1992). The reason for this is that there are many psychosocial issues associated with HD 
including emotional consequences of testing and decision-making (Chapman 1992). These need to 
be discussed to help make the result easier to deal with, regardless of whether it is positive or 
negative (Bloch, Adam, Wiggins et al. 1992).  
 
Part of the genetic counselling session will involve exploring the individual’s feelings around HD 
as well as their experiences of the disease, discussing their motivation for entering the HD 
predictive testing program, and helping them to think about how they may feel and what their 
future plans may be if the result is negative or positive (van 't Spijker and ten Kroode 1997). 
During these sessions the counsellor may also be alerted to difficulties in the individual’s life, such 
as depression, suicidal ideation, relationship difficulties and denial, which need to be carefully 
addressed before the individual continues with predictive HD testing (Chapman 1992).   
 
Many emotions can be present in individuals wanting to undergo predictive HD testing. These can 
include fear and anxiety regarding the test result, and its impact on their future and their children’s 
future (van 't Spijker and ten Kroode 1997). Individuals may also experience depression, 
uncertainty, confusion and/or anger towards an affected parent or unaffected sibling (Forrest 
Keenan, Miedzybrodzka, van Teijlingen et al. 2007). Many emotions may arise as a result of 
witnessing a parent’s struggle with HD, or from a family member’s predictive/diagnostic test result 
(Forrest Keenan et al. 2007). There may also be issues regarding their own identity and their 
expected status and what finding out their status will do to this identity (Bloch et al. 1992; 
Chapman 1992; Huggins, Bloch, Wiggins et al. 1992). There is also the possibility of 
discrimination against a person who tests positive for HD with regard to employment opportunities 
and insurance coverage (Quaid and Morris 1993; Almqvist, Bloch, Brinkman et al. 1999) 
 
For many patients, undergoing predictive testing for HD can by very stressful, regardless of the 
outcome of the test (Almqvist, Brinkman, Wiggins et al. 2003). Problems following predictive 
testing can include sadness, low self-esteem, anxiety, suicidal ideation, aggression, irritation, 
obsessions and compulsions (Witjes-Ane ,´ Vegter-van der Vlis, van Vugt et al. 2003). A study by 
Codori, Slavney, Rosenblatt (2004) showed that approximately 20% of patients undergoing 
predictive HD testing, who test positive, experience depression severe enough to require treatment, 
and a small percentage of individuals (about 6.9%) who test positive for HD cannot cope with the 
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result, and this may lead to “catastrophic events” (Almqvist et al. 2003). This could include severe 
depression, hospitalization or suicide (Almqvist et al. 2003). The reason for this is thought to be an 
identity crisis, with most of these catastrophic events or adverse reactions occurring within a year 
of receiving the positive result (Almqvist et al. 2003). However, long term studies have shown that 
most individuals are eventually able to deal with the results and integrate the new information into 
their lives (Almqvist et al. 2003).  
 
A positive HD result may also put a strain on a relationship, as the result may drastically change 
the dynamics of a relationship (van 't Spijker and ten Kroode 1997). The individual who tested 
positive for HD may become concerned about being a burden to their partner as their disease 
progresses, or may fear being abandoned by their partner as their symptoms start to show 
(Tassicker 2005). Individuals with HD may also start to suffer from various psychiatric problems 
including irritability, depression and suicidal ideation which may place a strain on their partner 
(Purdon et al. 1994; Young 2003). There is also a 50% chance that an affected individual’s 
children may inherit the gene. This may result in many emotional reactions, such as guilt and 
worry (van 't Spijker and ten Kroode 1997).  
 
There are also psychosocial effects when the outcome of the predictive HD test is negative. 
Individuals may experience relief and happiness that they tested negative for HD and that their 
children are no longer at risk of inheriting HD (van 't Spijker and ten Kroode 1997). It may also 
have positive effects with regard to medical aid rates and coverage as well as employment 
opportunities (Quaid and Morris 1993). Individuals who test negative for HD may feel that they 
can now make different decisions regarding studying, travelling and having a family, knowing that 
they are not at risk of developing HD (Huggins et al. 1992). They may also feel relieved that they 
will not be a burden to others due to HD progression (Huggins et al. 1992). 
 
A negative result may not always bring feelings of relief and happiness (Reviewed in van 't Spijker 
and ten Kroode, 1997). A small percentage of individuals who test negative for HD cannot cope 
with the result (Huggins et al. 1992). These individuals may have expected to test positive for HD, 
and may have made life decisions based on the anticipated result, making the negative result 
difficult to deal with (Meiser and Dunn 2001). If an individual’s siblings or other family members 
have tested positive for HD, an unaffected individual may also experience “survivor” guilt 
(Huggins et al. 1992; van 't Spijker and ten Kroode 1997; Decruyenaere, Evers-Kiebooms, 
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Boogaerts et al. 2005). Survivor guilt occurs when an individual tests negative for HD and 
experiences guilt due to other family members having tested positive (van 't Spijker and ten 
Kroode 1997).  
 
1.6.4 Prenatal HD testing issues 
 
Individuals who know they are affected or at risk of having inherited HD, may choose to have 
prenatal testing in a pregnancy. There are many issues related to this such as testing options, 
consequences of testing and decision-making around TOP when a pregnancy is affected.  
 
Testing options include chorionic villus sampling (CVS) and amniocentesis, both of which are 
invasive procedures and are associated with a miscarriage risk. This needs to be discussed with the 
couple. There is also a 50% chance that the fetus will test positive for HD if a parent has the gene 
mutation. The genetic counsellor needs to discuss with the couple what they may choose to do 
should the prenatal HD test be positive. The options available include terminating the pregnancy 
because the fetus will develop HD later in life or continuing the pregnancy with this knowledge. 
This may raise issues related to termination of pregnancy, such as ethical dilemmas, religious and 
cultural beliefs and feelings of guilt, loss or regret. If a couple chooses not to terminate, issues arise 
regarding the parents’ knowledge of their child’s HD status and the removal of the child’s 
autonomy to decide whether or not to be tested (Richards and Rea 2005). As it is against the 
Division’s code of ethics to test minors (individuals under 18 years of age) for adult-onset 
disorders such as HD, couples who indicate that they will still continue a pregnancy if they receive 
a positive prenatal HD test, may be refused prenatal diagnosis in that pregnancy.  
 
Alternate reproductive methods such as donor eggs/sperm, adoption and pre-implantation genetic 
diagnosis (not available in South Africa) may also need to be discussed. The first step in pre-
implantation diagnosis (PGD) involves the fertilization of ova by sperm using in-vitro fertilization 
(Mateizel, De Temmerman, Ullmann et al. 2006). The zygotes are allowed to develop and at about 
day 3 when the embryos consist of approximately 6 cells, one cell is removed from each zygote 
(Mateizel et al. 2006). These cells are then tested for HD using direct mutation testing (Moutou, 
Gardes and Viville 2004; Mateizel et al. 2006). Only unaffected embryos are implanted into the 
uterus (Moutou et al. 2004) 
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The uptake of prenatal testing for HD is estimated to be between 8% and 18% (reviewed in 
Richards and Rea 2005). The reason for the low uptake rate is thought to be because many parents 
are against termination of pregnancy, especially when the condition has an onset in adulthood. 
Other psychological issues such as denial of the condition or hope of a cure for their child, if they 
are found to be positive for HD in the future, also comes into play (Richards and Rea 2005). 
 
1.7 TREATMENT FOR HUNTINGTON DISEASE 
 
There is currently no cure for HD. However, supportive treatments are available which may help to 
temporarily improve the quality of life of individuals with HD. These may include occupational 
therapy, speech therapy and physiotherapy and it is useful for the patient to see a psychologist and 
psychiatrist to help deal with depression and other mental changes. Ideally, individuals with HD 
should be cared for by a team including neurologists, psychiatrists, psychologists, occupational 
therapists, physiotherapists, speech therapists, social workers and genetic counsellors. Medication 
is also available to help reduce symptoms, such as antidepressants for psychological changes, and 
neuroleptics to suppress involuntary movements (Borrell-Pagès et al. 2006).  
 
Various drugs are now being researched because of their effect on the pathways involved in 
causing HD (Borrell-Pagès et al. 2006). These include antioxidants (e.g. Coenzyme Q10) which 
may improve mitochondrial function and increase BDNF levels, transcription regulators (e.g. 
mithramycin) which can improve motor and neurological function and anti-apoptotics and protein 
aggregation inhibitors, which may also be used as potential treatments for HD (Ferrante, 
Andreassen, Dedeoglu et al. 2002; Ferrante, Ryu, Kubilus et al. 2004; Gauthier et al. 2004; 
Borrell-Pagès et al. 2006). There has also been some success with newer treatments such as the 
injection of fetal neuroblasts and neural precursors into the striatum of affected individuals, 
thereby replacing degenerated neurons (Bachoud-Levi, Remy, Nguyen et al. 2000; Rosser, Barker, 
Harrower et al. 2002; Bachoud-Levi, Gaura, Brugieres et al. 2006). 
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1.8 PURPOSE OF THIS STUDY 
 
It is important to be aware of the number of patients seen for genetic counselling and testing for 
HD at the Division so that appropriate services can be planned for and provided. By being aware of 
any changes in uptake, it may be possible to adjust the services accordingly, by training additional 
genetic counsellors, for example, or raising awareness of the services that are available at the 
Division. This study also has implications for the molecular testing service at the Division as they 
would need to be prepared for an increase in the number of samples if it is found that the number 
of tests performed is increasing. If the number is decreasing, however, it may be necessary to 
undertake research to determine the cause of this decrease.  
 
Characterising the individuals who request predictive, prenatal or diagnostic HD testing is 
important as it provides insight into the patients and what their needs are. A better understanding 
of the patients who request these tests would be useful in the genetic counselling process and may 
help to improve the services offered. This study may also assist us in determining which sectors of 
the population make use of the services and which ones have limited access to the services.  
 
Another aim of this study was to continue a previous study done by Kromberg et al. (1999) where 
the utilization of predictive, prenatal and diagnostic testing for HD was investigated in the same 
Division between 1975 and 1997. The continuation of the study will enable trends in patient 
numbers to be noted, as well as highlighting any changes in who is being seen for predictive, 
prenatal and diagnostic HD testing over the years.  
 
1.9 AIM AND OBJECTIVES 
 
The aim of this study was to investigate the utilization and outcome of diagnostic, predictive and 
prenatal genetic testing for HD in Johannesburg from 1998 to 2006. The objectives were: 
 
1. To determine the number of patients who were referred to or managed by the genetic 
counselling or laboratory services in the Division with regard to diagnostic, predictive 
and/or prenatal HD testing. 
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2. To characterise the individuals requesting predictive and diagnostic HD testing, including 
their gender, age, employment and relationship status, number of children, ethnicity, HD 
test results and motivations for undergoing predictive HD testing.  
3. To assess the total number of patients who completed the HD predictive testing process and 
received a result and how long this took. 
4. To compare the characteristics of those who completed the HD predictive testing process to 
those who did not. 
5. To compare the characteristics of the patients who underwent diagnostic HD testing to 
those who went through the HD predictive testing process.   
6. To characterise the individuals who requested prenatal testing for HD including at-
risk/affected status, gender and age of the parent, gestational age and test result and to 
analyse the decisions made after HD prenatal testing results were given. 
7. To compare the patient numbers and patient characteristics observed in this study to those 
from a previous study done by Kromberg et al. (1999) in the same Division between 1975 
and 1997 to identify trends over time.  
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2 SUBJECTS AND METHODS 
 
2.1 SUBJECTS 
 
Subjects for this study included individuals who received genetic counselling for HD diagnostic, 
predictive or prenatal testing purposes and/or underwent genetic testing for HD through the 
Division of Human Genetics, National Health Laboratory Services, and the University of the 
Witwatersrand, Johannesburg, between January 1998 and December 2006. Patients may have had 
HD genetic counselling and/or genetic testing files and both were used, if available. Counselling 
files (see appendix A for an example) contain patient information, family history and counselling 
notes and a detailed patient report written to the referring doctor. HD genetic testing files contain 
limited patient information, test information and results. This study was retrospective and all files 
for these individuals were available in the Division. 
 
Only files of patients counselled or tested for HD between January 1998 and December 2006 were 
included. The reason for selecting this time range was that a previous study was done in the same 
Division, with the aim of analysing the utilization of predictive, prenatal and diagnostic HD testing 
in Johannesburg and included patients counselled and/or tested for HD in Johannesburg between 
January 1975 and December 1998 (Kromberg et al. 1999). This study aimed to continue the study 
to the present and assess changing trends compared to the previous study.   
 
Only individuals at risk of having inherited HD, or who were tested for the disorder were included 
in this study. Files for 287 individuals where diagnostic, predictive or prenatal HD testing was 
requested at the Division, from January 1998 until December 2006 were included in this study. 
There were 221 files where diagnostic HD testing had been requested, 57 where predictive HD 
testing was requested and 9 files for prenatal HD testing. All 221 individuals for whom diagnostic 
HD testing was requested had molecular testing files, and sixty-one (27.3%) of these individuals 
also had HD genetic counselling files. All individuals in the predictive HD testing group had 
genetic counselling files, and 38 individuals had molecular testing files for HD. All nine couples 
who requested prenatal HD testing had genetic counselling files and seven had HD prenatal 
molecular testing files.  
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All individuals of black or mixed ancestry who had diagnostic testing for HD were tested for both 
HD1 and HDL2, while white and Indian individuals were only tested for HD1. Individuals who 
requested predictive HD testing were tested for an expansion in either the IT15 (HD1) or JPH3 
(HDL2) gene, whichever had been found in their affected family member/s.   
  
2.2 DATA COLLECTION 
 
After an individual has been seen for genetic counselling, their name and the date of the session are 
written onto filing cards for each disorder and kept in a filing system. The names and date of 
testing of all individuals who have had molecular genetic testing for HD are stored in a separate 
database in the Molecular Genetics Laboratory and each family that has HD testing is allocated an 
HC (Huntington’s chorea) number. Names and HC numbers of individuals who had genetic testing 
for HD between 1998 and 2006 were collected using the Molecular Genetics Laboratory database, 
while a list of patients who received genetic counselling for HD during this time period was 
obtained from the filing cards for HD. Molecular and counselling files for each of these patients 
were then drawn from the storage and filing facilities within the Division 
 
For this study, each patient was randomly allocated a unique subject number which, along with the 
individual’s name and HC number (if applicable), was typed into a master list. Only the researcher 
and her supervisors had access to the master list. Patients were then classified as predictive, 
diagnostic or prenatal, and information from their molecular and/or genetic counselling files was 
written onto the appropriate data collection sheets (refer to appendix B), along with their unique 
subject number that had been allocated earlier. To ensure anonymity, the data sheets did not 
contain any identifiable information such as patient names or HC numbers and patients were 
identified only by their subject number throughout the study. Individuals who had a genetic 
counselling file (and who may also have had a molecular testing file) were marked on the data 
collection sheets as having received genetic counselling, while those who had only molecular files 
were marked on the data collection sheets as not having received genetic counselling. All 
individuals who receive genetic counselling in the Division will have a genetic counselling file.   
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2.2.1 Information collected about individuals who had genetic counselling and/or testing for 
HD 
 
General information was collected for all patients. This information included their date of birth, 
gender, ethnicity (white, black, Indian, mixed ancestry), relationship status (single, 
divorced/separated, widowed, married/in relationship), employment status (employed, 
unemployed, retired, student), number of children, test result (positive for HD1, positive for 
HDL2, negative, not tested/no result). The ethnicity of the individuals was obtained from an 
existing HD patient database at the NHLS. This information is collected (where possible) by the 
laboratory as it is needed for accurate DNA testing. Other information was available from notes in 
the patients’ counselling or molecular files. Where information such as ethnicity, relationship 
status, employment status and/or number of children was not written in the patient’s file, the data 
sheet for that individual was marked as “unknown” for that characteristic.  
 
2.2.2 Information collected about individuals who had diagnostic HD testing  
 
Individuals in the diagnostic HD testing category included patients referred for genetic testing for 
HD because they were already showing symptoms suggestive of this disorder. It also included 
patients who attended the Genetic Counselling Clinic for predictive HD testing and were found to 
be symptomatic by the psychiatrist or neurologist while going through the predictive testing 
protocol. Information about HD diagnostic patients who did not receive genetic counselling was 
limited, as the only information available was from their referral forms and test request forms.  
 
In addition to the general information documented for all patients (section 2.2.1), the following 
information was also obtained from the files of patients who underwent diagnostic testing (where 
possible) and written onto data collection sheets: 
- Date of the test (if done) 
- Age at the time the test was done 
- Reason for the test not completed (if applicable) 
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2.2.3  Information collected about individuals who had HD predictive genetic counselling 
and/or testing 
 
The predictive testing category included all individuals who began the HD predictive testing 
protocol by attending the first genetic counselling session. Where an individual initially attended a 
genetic counselling session wishing to undertake HD predictive testing but was then found to be 
symptomatic, they were reclassified as diagnostic. However, it was noted that they initially 
requested predictive testing.  
 
In addition to information collected as described in section 2.2.1, the following additional 
information was obtained from the files of the HD predictive testing patients (where possible) and 
written onto data collection sheets: 
- Date of first genetic counselling session 
- Age at first genetic counselling session 
- Date of entry into the predictive program 
- Age at time of entry into the predictive program 
- Date of result-giving session 
- Age at result-giving session 
- Motivation for undergoing HD predictive testing  
 
2.2.4 Information collected about prenatal HD testing 
 
Prenatal testing involves an at-risk individual or an individual who has been confirmed to have HD 
requesting testing of a fetus during pregnancy. The fetal cells can be obtained by either CVS or by 
amniocentesis and are tested in order to determine whether or not the fetus is at risk of developing 
HD.  
 
The following additional information was obtained from the files of patients who underwent 
prenatal testing and written onto data collection sheets: 
- HD status of parent (i.e. affected or at 50% risk) 
- Gender of affected/at risk parent 
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- Age of affected/at risk parent at time of test 
- The year when the test was requested  
- Gestational age at time CVS or amniocentesis was performed. If CVS/amniocentesis was not 
done, the gestational age at the time of attendance of the first genetic counselling session was 
used.   
- Decision made after a positive HD result (i.e. termination or continuation of pregnancy) 
 
2.3 DATA ANALYSIS 
 
This study involved retrospective analysis of data obtained from files of individuals who had 
diagnostic, predictive or prenatal HD testing through the Division between January 1998 and 
December 2006.  
 
All information obtained from the data sheets was entered into Excel spreadsheets under the 
headings of diagnostic, predictive and prenatal HD testing.  
 
Frequency calculations were used for each group (diagnostic, predictive and prenatal) to 
determine: the number of males and females; the number of individuals of white, black, Indian, 
mixed or unknown ancestry; the number of individuals in a relationship and the number not in a 
relationship; the number of employed and unemployed individuals; how many individuals had 
children and how many did not; the number of individuals who tested positive for HD1 and HDL2 
and the number who tested negative for HD; the number of individuals within different age groups; 
and the number of tests done each year. Frequencies were reported as percentages (%) to one 
decimal place.  
 
Excel was used to determine the median age of individuals in each group, as well as the median 
time taken to complete the HD predictive testing process. The “Median” and “Standard Deviation” 
functions in Excel were used for this. Standard deviation results were rounded to one decimal 
place.  
 
Fisher’s exact and Mann-Whitney U tests were performed using statistical software available on 
the internet (Graphpad Quickcalcs and IFA Service Statistics respectively). The Fisher’s exact test 
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was used in this study to determine whether there was any association between two variables. The 
null hypothesis (H0) is that the variables are independent, and a p-value is generated to enable H0 
to be accepted or rejected (Raymond and Rousset 1995). It can be used for small population sizes 
(less than 5) rather than the similar χ2 test, which is only accurate for larger sample groups. For 
Fisher’s exact tests where the two variables being compared each had more than two values (i.e. 
not a 2x2 comparison using a 2x2 contingency table), a 2x5 contingency table Fisher’s exact test 
was done using Simple Interactive Statistical Analysis (SISA) software which was also available 
online. The Mann-Whitney U test was used in this study to assess whether there was a significant 
difference between the medians from two sample groups. For both the Fisher’s exact and the Mann 
Whitney U test, a p value of less than 0.05 was considered to be statistically significant. A 
statistician at the University of the Witwatersrand was consulted to validate the results obtained 
and to ensure that the correct tests were used.  
 
2.4 ETHICS 
 
Ethics clearance (protocol number M060945) was obtained from the Human Research Ethics 
Committee (Medical) on 29 September 2006 (See appendix C). Ethics clearance for this project 
was given subject to limiting data collection until October 2006. This limitation was appealed 
(appendix D) as the aim of this project was to assess the utilization and outcome of diagnostic, 
predictive and prenatal testing for HD in Johannesburg between 1 January 1998 and 31 December 
2006.  
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3 RESULTS 
 
 
The number of patients who requested diagnostic, predictive and prenatal testing for HD between 
1998 and 2006, as well as the number of tests that were requested each year in the Division, are 
presented in section 3.1. 
 
The section on patients who had diagnostic testing gives an overview of the patient demographics, 
as well as a description of their test results analysed by gender, ethnicity and age. The 
demographics of patients who had predictive testing, their motivations for undergoing HD 
predictive testing and their test results are also shown. The section on prenatal testing describes the 
demographics of the individuals who requested prenatal testing for HD, as well as the results of 
any prenatal tests performed. The decisions parents made regarding termination or continuation of 
the pregnancy following a positive HD result are also presented.  
 
A final section in this chapter includes two sets of comparisons. Firstly the demographics of the 
patients who had diagnostic and predictive HD testing are compared, and secondly the results 
found in this study are compared to those of a study done by Kromberg et al. (1999). 
 
3.1 PATIENT NUMBERS AND TESTS PER YEAR 
 
3.1.1 Number of diagnostic, predictive and prenatal HD patients 
 
Files were available for 291 individuals for use in this study. These files were from individuals 
who requested predictive or prenatal testing for HD, as well as for individuals for whom diagnostic 
HD testing was requested. Four of these 291 files were excluded. One was excluded because it was 
a request for testing of an adopted baby who was potentially at-risk of having inherited HD. 
Another was excluded as it was a request by a woman to have her positive HD predictive testing 
result confirmed. She had been tested by a private laboratory and had not been through the 
predictive testing process. The remaining two files were excluded as they were requests for 
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predictive testing but the individuals did not attend a genetic counselling session. The other 287 
files were included in this study.  
 
As can be seen from Figure 3-1, 77% of records obtained between 1998 and 2006 for HD were 
diagnostic. Predictive testing for HD was the next most requested service, comprising 20% of the 
sample group. Only a small proportion (3%) of at-risk or affected individuals requested prenatal 
testing and/or counselling for HD between 1998 and 2006. 
 
 
Diagnostic 
77% (221)
Predictive  
20% (57)
Prenatal    
3% (9)
 
 
Figure 3-1: Number and percentage of diagnostic, predictive and prenatal records for individuals 
who had genetic counselling and/or genetic testing for HD between January 1998 and December 2006 
by the Division. 
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3.1.2 Number of diagnostic, predictive and prenatal HD tests requested per year between 
1998 and 2006 
Figure 3-2: The number of patients who requested prenatal testing and/or counselling for HD (in 
green) , the number of patients who requested predictive HD testing and/or counselling (blue) as well 
as the number of patients for whom molecular genetic diagnostic testing for HD was requested (pink) 
at the Division each year from 1998 to 2006.  
 
As shown in Figure 3-2, there has been a general increase in the number of both predictive and 
diagnostic tests done for HD between 1998 and 2005. The increase has not been consistent and a 
decrease in the number of diagnostic tests performed in 2006 is evident.  
 
The number of prenatal tests and/or prenatal HD counselling sessions requested each year has 
remained low with no prenatal HD tests or prenatal HD genetic counselling sessions being 
requested between 2003 and 2006. Of the nine prenatal HD genetic counselling sessions done, only 
five different couples were involved. Three couples received prenatal HD genetic counselling 
and/or testing for one pregnancy, one couple requested prenatal HD genetic testing for two 
pregnancies, while another couple had three pregnancies tested prenatally for HD (including a twin 
pregnancy). 
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3.2 DIAGNOSTIC TESTING FOR HD 
 
Diagnostic testing for HD was requested for a total of 221 individuals between January 1998 and 
December 2006. Five of these individuals had requested predictive testing but were found to have 
symptoms of HD after consultation with a neurologist during the predictive testing process, and 
were offered diagnostic testing. Sixty-one of the 221 individuals (27.3%) for whom diagnostic 
testing was requested received genetic counselling for HD. Of these 61 individuals who received 
genetic counselling for HD, 44 (72.1%) tested positive for HD1, three (4.9%) tested positive for 
HDL2, ten (16.4%) tested negative for HD and four (6.6%) were not tested.  
 
3.2.1 Characteristics of patients from whom diagnostic HD testing was required 
 
Gender, ethnicity, relationship status, employment status, number of children and age of 
individuals for whom diagnostic testing for HD was requested, were analysed in this study. These 
results are shown in Table 3-1 and Table 3-2. 
 
Table 3-1: Characteristics of the 221 individuals for whom diagnostic testing for HD was requested 
between January 1998 and December 2006. 
 
Characteristic Total           % Characteristic Total           % 
 
 
 
 Gender  Number of Children  
   Female 115               52    No children 24             10.8 
   Male 105            47.5    1 or more children  70             31.7 
   Unknown 1                  0.5    Unknown 127           57.5 
  
 
 
Relationship Status  Age  
   Not in relationship a                   25             11.3    Under 30 21                 9.5 
   In a relationship/Married 68             30.8    30-39     35               15.8 
   Unknown 128           57.9    40-49     41               18.6 
     50-59     45               20.4 
Employment Status     60-69     32               14.5  
   Employed 30             13.6    Over 70     12                 5.4 
   Not employed b 36             16.3    Unknown     35               15.8 
   Unknown 155           70.1   
a
 Included 14 single, 6 divorced and 5 widowed individuals 
b
 Included 20 unemployed individuals, 8 students and 8 retired individuals 
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As shown in Table 3-1 the number of males and females in the diagnostic testing group was not 
statistically different from the expected population ratio of 48 males: 52 females (p=1.00; Fisher’s 
exact test). This ratio was calculated using data from the South African population census 2001, 
where 47.8% of individuals were male and 52.2% were female. The relationship status, 
employment status and number of children for many individuals who had diagnostic HD testing 
was unknown. Of the individuals whose relationship status was known, more than twice as many 
were in a relationship than not. The number of individuals employed and the number unemployed 
was not significantly different (p=0.16; Fisher’s exact test) from the general South African 
population, where 58.4% of individuals are employed and 41.6% are unemployed (Statistics South 
Africa 2001). Approximately 32% of individuals in the diagnostic testing group had one or more 
children compared to about 11% who had no children, although the number of children was 
unknown for 57.7% of the individuals.  
 
The age range of individuals for whom diagnostic testing for HD was requested between 1998 and 
2006 was 3 to 84 years, with a median age of 49 years (SD±15.4). Two individuals, one aged 20 
and one aged 51, had already died when their tests were performed. Their ages at the time of death 
were noted, as this was the time at which their blood was taken. 
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Table 3-2: South African population divided by ethnic groups according to the 2001 South African 
Population Census, and the observed number of patients for whom diagnostic testing for HD was 
requested between 1998 and 2006 divided by ethnic groups.  
 
Population Group % in population 
Observed number  
of patients 
Expected number  
 of patientsa 
Black African 79% 93         (43.5%) 169.06     (79%) 
White 9.6% 106       (49.5%) 20.54      (9.6%) 
Coloured 8.9% 11         (5.1%) 19.05      (8.9%) 
Indian or Asian 2.5%  4          (1.9%) 5.35        (2.5%) 
Total 100% 
 214 b  214 b 
a
 Expected values were calculated from the population percentages obtained from the South African Census 
2001 data using the following formula: (diagnostic sample size of 214) x (proportion of individuals in each 
ethnic group). This was done to obtain the number of individuals of white, black, Indian and mixed ancestry 
in a sample of 214 individuals, based on the percentage of individuals in each ethnic group in the general 
South African population, expected to require HD diagnostic testing. Gene frequency has been assumed to 
be equal in all population groups, which may not be valid.  
b Total used was 214 and not the total sample group of 221 because 7 individuals were of unknown 
ethnicity (3.2%).  
 
The number of individuals in each ethnic group for whom HD diagnostic testing was requested 
was significantly different from the calculated expected numbers in each ethnic group based on the 
2001 South African Population Census (p<0.001 using Fisher’s exact test). The observed 
percentage of white individuals who had diagnostic testing (49.5%) was higher than the expected 
percentage of 9.6%. For the other three population groups (black, Indian and mixed ancestry), the 
observed percentage of individuals was lower than the expected percentages (Table 3-2) 
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3.2.2 HD diagnostic test completion 
 
Thirteen of the 221 (5.9%) diagnostic tests requested were not completed. The reasons for this are 
shown in Table 3-3. 
 
Table 3-3: The reasons for HD diagnostic testing not being completed in thirteen cases, at the 
Division.  
 
Reason for test not completed Number of samples 
Incorrect tube    6 
Test cancelled by doctor a    2 
Forms incomplete b    2 
Doctor wanted to confirm diagnosis clinically first c    2 
Test requested by daughter d    1 
Total   13 
a Doctor no longer felt that the patient’s symptoms were due to HD 
b Incomplete forms did not include patient details or did not include details of the test requested and the 
reason for the test being requested 
c
 The doctor felt he wanted to first determine whether the patient’s symptoms were suggestive enough of 
HD before doing a diagnostic test 
d Sample was rejected as it was sent in by a woman requesting that her father’s blood be tested for HD 
 
3.2.3 HD diagnostic test results 
 
 
 
 
 
 
 
 
 
Figure 3-3: The outcomes of diagnostic testing for HD1 and HDL2 requested between January 1998 
and December 2006 at the Division. 
 
Not tested             
6% (13)
Tested   
94% (208)
Positive HD1              
44% (92)
Negative      
47% (97)
Positive HDL2              
9% (19)
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As shown in Figure 3-3, HD diagnostic testing was completed for 208 patients (94%), and of these, 
92 tested positive for HD1 and 19 tested positive for HDL2. All black and mixed ancestry 
individuals were tested for HDL2 as it has been found to occur in these population groups. HDL2 
has not been found to occur in the white and Indian population groups, so individuals of these 
ethnicities were not tested for HDL2.  
 
The number of children was unknown for 47 of the individuals who tested positive for HD (HD1 
or HDL2), but was known for the other 64. These 64 HD positive individuals had 160 children 
between them, all of whom are at 50% risk of having inherited HD.  
 
Table 3-4: The number of individuals, by gender, who had HD diagnostic testing and tested either 
positive or negative for HD1 or HDL2.  
The total number tested is 208 rather than 221, as these results do not include the 13 individuals not tested 
for HD (see Table 3-3). 
 
 
As seen in Table 3-4 the number of males and females receiving either a positive result or a 
negative result was similar (p=0.40; Fisher’s exact test). Gender did not also appear to have an 
effect on whether an individual tested positive for HD1 or HDL2 (p=0.80; Fisher’s exact test).  
 
 
 
 
 
 
 
 
 
 
 
Gender 
Total 
number 
tested 
Positive 
Negative (%) 
HD1    HDL2   Total  (%) 
     Male 100 45      8       53    (53.0) 47     (47.0) 
     Female 107 52      11      63    (58.9) 44     (41.1) 
     Unknown 1 0 0 0 1         
     Total 208 97 19 116 92 
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Table 3-5 : The number of individuals, by ethnic group, who had HD diagnostic testing and tested 
either positive or negative for either HD1 or HDL2.  
The total number tested is 208 rather than 221, as these results do not include the 13 individuals not tested 
for HD (see Table 3-3). 
 
 
As seen in Table 3-5, when comparing white individuals to black individuals, significantly more 
white individuals tested positive than negative while more black individuals tested negative than 
positive (p=0.04, Fisher’s exact test). 
Figure 3-4: The number of individuals in the diagnostic group who tested positive for either HD1 or 
HDL2 in each ethnic group. 
 
 
Ethnicity 
Total number 
tested 
Positive (%)  
for HD1 or HDL2 
Negative (%) 
     White 101 62    (61.4) 39     (38.6) 
     Black 87 40    (46.1) 47     (54.0) 
     Mixed Ancestry 11 7      (63.6) 4       (36.4) 
     Indian 4 3      (75.0) 1       (25.0) 
     Unknown 5 4      (80.0) 1       (20.0) 
     Total 208 116 92 
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Individuals who tested positive for HDL2 were black, or of mixed ancestry, as can be seen from 
Figure 3-4. White individuals were not tested for HDL2 because HDL2 has not been found to 
occur in this population group. Amongst the black individuals in the diagnostic group, 35% of the 
individuals who tested positive for HD were positive for HDL2. In the mixed ancestry group, 43% 
of the HD positive individuals tested positive for HDL2. Overall, there was no significant 
difference been the number of black and mixed ancestry individuals testing positive for HD1 and 
the number testing positive for HDL2 (p=0.69; Fisher’s exact test).  
 
Table 3-6: The number of individuals, by age, who had HD diagnostic testing and tested positive for 
HD1 or HDL2 and the number who tested negative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A positive test result (positive HD1 or HDL2) seemed to be dependent on age (p=0.047; Fisher’s 
exact test) with most individuals (64.9%) who tested positive for HD being between the ages of 30 
and 69, as shown in Table 3-6. Individuals outside this age range were more likely to test negative 
for HD than positive. The most common age range during which individuals were tested for HD 
diagnostically was 50-59 years (21.2%), followed by 40-49 years (18.7%).  
Age 
Total number 
tested (% of total) 
Positive (%) 
for HD1 or 
HDL2 
Negative (%) 
     Under 30 21       (10.1) 5       (23.8) 16     (76.2) 
     30-39 37       (17.8) 24     (64.9) 13     (35.1) 
     40-49 39       (18.7) 27     (69.3) 12     (30.7) 
     50-59 44       (21.1) 31     (70.5) 13     (29.5) 
     60-69 17         (8.2) 16     (94.1) 1         (5.9) 
     Over 70 12         (5.8) 3       (25.0) 9       (75.0) 
     Unknown 38       (18.3) 10     (26.3) 28     (73.7) 
     Total 208 116 92 
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Figure 3-5: The number of individuals in the diagnostic group who tested positive for HD1 and the 
number who tested positive for HDL2 in each ethnic group. 
 
 
The median age of individuals who tested positive for HDL2 was 55 years (SD± 9.3), which was 
significantly older than the median age of 48 years (SD±12.2) for the individuals who tested 
positive for HD1 (p=0.03; Fisher’s exact test). As seen in Figure 3-5, most individuals who tested 
positive for HDL2 were between the ages of 50 and 59 years, while most individuals who tested 
positive for HD1 were between 40 and 49 years of age. 
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Figure 3-6: The median age of individuals at the time of either a positive HD1 or a positive HDL2 
diagnosis, shown by ethnicity. No white or Indian individuals were tested for HDL2.  
 
As seen in Figure 3-6, the median age of white individuals who tested positive for HD1 was 48 
years (SD±11.7). The median age of black individuals testing positive for HD1 was 49 years 
(SD±11.9), and was 56 years for HDL2 (SD±8.6). Individuals of mixed ancestry who tested 
positive for HD1 had a median age of 39.5 years (SD±17.4) and those who tested positive for 
HDL2 had a median age of 52 years (SD±13.1). The median age at testing for Indian individuals 
was 31 years (SD±2.7). There were no significant differences found between the median ages at 
diagnosis in the different ethnic groups. The Indian sample size (3) is too small to draw significant 
conclusions.  
 
3.3 PREDICTIVE TESTING FOR HD 
 
3.3.1 Completion of HD predictive tests 
 
A total of 57 patients from 49 families requested predictive testing and/or attended a genetic 
counselling session regarding HD between January 1998 and December 2006. As shown in Figure 
3-7, 38 of these individuals completed the predictive testing process by seeing a genetic counsellor 
at least twice, a neurologist, psychologist and psychiatrist and receiving a result. Three individuals 
attended an initial session with a neurologist, psychologist or psychiatrist after having a genetic 
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counselling session, but did not complete the predictive testing process. Sixteen individuals only 
attended one genetic counselling session and did not pursue predictive HD testing.  
 
Figure 3-7: Number of sessions attended by individuals who requested predictive testing for HD at 
the Division between 1998 and 2006.  
A “session” was defined as an appointment with a genetic counsellor, neurologist, psychologist or 
psychiatrist as part of the predictive testing process. All these professionals needed to be seen and a result 
received in order for an individual to complete the predictive testing process.  
 
The number of days taken to complete the predictive HD testing process, from the initial session to 
the result giving session ranged from 17 days to 771 days (approximately 2 years and 2 months). 
The individual who took only 17 days to complete the process had already seen a neurologist, 
psychologist and psychiatrist just before attending the initial genetic counselling session and was 
not required to see these professionals again. The median time taken to complete the process was 
125.5 days (approximately 4 months; SD±156.6), with only four of the 38 individuals who 
completed the process taking longer than 1 year to do so. One of these individuals lived in a 
country bordering South Africa, and experienced a delay in completing the predictive testing 
process due to travelling difficulties.  
 
3.3.2 Characteristics of patients who requested predictive HD testing 
 
A number of characteristics of the individuals requesting predictive testing for HD were analysed 
in this study. These included gender, ethnicity, relationship status, employment status and number 
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of children (Table 3-7). None of these factors was found to significantly influence whether or not 
the HD predictive testing process was completed (Refer to Appendix E). 
 
Table 3-7: Characteristics of the 57 individuals who requested predictive testing for HD at the 
Division between 1998 and 2006.  
 
Characteristic Total     % Characteristic Total    % 
 
 
 
 Gender   Number of Children  
   Female 38         (66.7)    No children 31         (54.4) 
   Male 19         (33.3)    One or more children  25         (43.9) 
     Unknown 1             (1.7) 
Relationship Status    
   Not in relationship a                    16         (28.1)   
   In a relationship/Married 40         (70.2) Age  
   Unknown 1             (1.7)    Under 20 3            (5.3) 
     20-29 24        (42.1) 
Employment Status     30-39 20        (35.1) 
   Employed 42         (73.7)    40-49 6          (10.5) 
   Not employed b 13         (22.8)                              Over 50 4            (7.0) 
   Unknown 2             (3.5)   
    
a
 Included 13 single, 2 divorced and 1 widowed individual 
b
 Included 10 unemployed individuals and 3 students 
 
In the predictive testing group, approximately 67% of individuals who requested testing were 
female. This is significantly different from the expected ratio of 50% female to 50% male (p=0.02; 
Fisher’s exact test) for a dominant disorder. More than 70% of individuals in the predictive testing 
group were married or in a relationship, and 43.9% had one or more children. With regard to 
employment status, about 74% of individuals in the predictive testing group were employed, which 
is not significantly different (p=0.07; Fisher’s exact test) from the general South African 
population, where 58.4% of individuals are employed and 41.6% are unemployed (Statistics South 
Africa 2001). The age range of individuals who requested HD predictive testing was 18-56 years, 
with a median age of 30 years (SD±8.88).  
 
 
 
Results 
 
 39
Table 3-8: South African population divided by ethnic groups according to the 2001 South African 
Population Census and the observed number of patients who requested predictive testing for HD 
between 1998 and 2006, divided by ethnic groups.  
 
Population Group % in population 
Observed number  
of patients requesting 
HD predictive testing 
Expected number  
of patientsa 
Black African    79% 2           (3.5%) 45.03      (79%) 
White    9.6% 52         (91.2%) 5.47       (9.6%) 
Coloured    8.9% 2           (3.5%) 5.07       (8.9%) 
Indian or Asian    2.5% 1           (1.8%) 1.43       (2.5%) 
Total    100% 57         (100%)  57 
a
 Expected values were calculated from the population percentages obtained from the South African 2001 
Census data using the following formula: (predictive sample size of 57) x (proportion of individuals in each 
ethnic group). This was done to obtain the number of individuals of white, black, Indian and mixed ancestry 
in a sample of 57 individuals, based on the percentage of individuals in each ethnic group in the general 
South African population, who would be expected to request predictive testing for HD. This was calculated 
assuming an equal gene frequency in all population groups, which may be incorrect.  
 
As shown in Table 3-8, more white individuals requested predictive testing than any of the three 
other groups (black, Indian and mixed ancestry). This was significantly different from the number 
of individuals in each ethnic group who would be expected to request HD predictive testing based 
on the make-up of the South African population (Statistics South Africa 2001) (p<0.001; Fisher’s 
exact test). However, we have assumed equal gene frequency in the different ethnic groups, which 
may be incorrect. The calculation is also based on only 57 individuals requesting predictive testing 
for HD.   
 
3.3.3 Motivation of individuals in the predictive HD testing group for entering the HD 
predictive testing process 
 
Four common reasons for entering the HD predictive testing process to find out whether or not one 
will develop HD have been described in the literature (Evers-Kiebooms, Swerts, Cassiman et al. 
1989; Meissen, Mastromauro, Kiely et al. 1991; Quaid and Morris 1993; Lucas 1998). In this 
study, the same motivations were named by patients. These include: 
 decrease uncertainty            
 plan for the future  (including financial, marital and career decisions) 
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 aid in reproductive decision-making                  
 inform children of their risks 
 
The motivation for entering the predictive testing program was obtained from notes written in the 
genetic counselling files for 53 of the 57 individuals who requested predictive testing for HD. 
Three of these 53 individuals were unsure if they wanted to be tested, and had requested genetic 
counselling to obtain more information, but did not enter the predictive testing program. Twenty-
nine of the individuals who requested predictive testing gave only one main reason for doing so, 
nineteen gave two reasons and two individuals gave three reasons for requesting HD predictive 
testing. For this reason, the numbers in Figure 3-8 below exceed 50. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-8: Individuals who entered the predictive testing process had different motivations for doing 
so. These motivations, as well as the number of individuals who gave each motivation, are shown.  
Some individuals had more than one motivation for requesting HD predictive counselling and/or testing. 
 
 
Four of the individuals who requested predictive testing for HD gave other reasons for wanting to 
know their status and these included feeling that they had symptoms and wanting to be sure (3 
individuals), and the test being requested by their pension or insurance fund (1 individual). 
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3.3.4 HD predictive test results 
 
 
Figure 3-9: The chart on the left shows the number and percentage of HD predictive tests that were 
completed between January 1998 and December 2006 at the Division. On the right are the results of 
the completed HD predictive tests, including the number of individuals who tested positive for HD1, 
the number who tested positive for HDL2 and the number who tested negative for HD.  
 
Of the total number of patients who requested predictive testing for HD, approximately 67% 
completed the process. As can be seen from Figure 3-9, 14 individuals tested positive for HD1, one 
patient tested positive for HDL2 (this was an individual of mixed ancestry who was a member of a 
large family confirmed to have HDL2 by diagnostic testing) and 23 individuals tested negative for 
HD (including one individual who tested negative for HDL2). All individuals who requested 
predictive testing for HD were at 50% risk so it was expected that 50% of the individuals tested 
would test negative for HD and 50% would test positive for HD. The results of this study were not 
significantly different from expected (p=0.50; Fisher’s exact test). 
 
 
 
 
 
 
 
 
 
 
Positive HD1
 36.9% (14)
Positive HDL2 
2.6% (1)
Negative
 60.5% (23)
Tests completed
 66.7% (38)
Tests not 
completed
 33.3% (19)
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3.4 PRENATAL HD TESTING 
 
Nine prenatal tests for HD were requested by five different couples between January 1998 and 
December 2006.  
 
Table 3-9: Characteristics of individuals who requested prenatal testing for HD, including their 
gestational age at the time of the test, the gender, age and HD status of the affected or at-risk parent, 
as well as the result of the prenatal HD test and the decision the parents took following a positive HD 
result. 
 
Couple HD status 
 of parent 
Gender  
of at-risk 
parent 
Age of 
at-risk 
parent 
Year of 
pregnancy 
Gestational 
age (weeks) 
Prenatal 
result Decision 
1 50% risk Female 24 1999 12 Not tested 
Continued 
pregnancy 
2 50% risk Female 34 1999 12 Not tested Continued pregnancy 
3 
 
 
 
Positive 
 
 
Female 
26 1998 Unknown Negative Continued 
pregnancy 
29 2000 10 (twin 1) Positive TOPb 
29 2000 10 (twin 2) Positive TOPb 
30 2002 10 Negative Continued 
pregnancy 
 
4 
 
Positive 
 
Male 
31 2002 11 Positive TOPb 
31 2002 11 Negative Continued 
pregnancy 
5 Positive Male 41 2002 12 
Negative 
(47XXX)a 
Continued 
pregnancy 
a Karyotype analysis is routinely done on all prenatal samples. 
b TOP = Termination of pregnancy 
 
As seen in Table 3-9, the gestational age at the time the HD prenatal test was requested was 
unknown for one patient, but for all others the tests were requested between 10 and 12 weeks 
gestation. Three of the five individuals requesting HD prenatal testing and/or prenatal HD genetic 
counselling were positive for HD and had been through the predictive HD testing process, while 
the other two individuals were at 50% risk. Two male and three female probands requested genetic 
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counselling to find out about HD prenatal testing. The age range of the individuals requesting HD 
prenatal testing was 24 - 41 years. All individuals who requested prenatal testing were white, 
married and employed (not shown in Table 3-9).  
 
Two of the five couples who requested prenatal counselling for HD chose not to continue with a 
test on the pregnancy. In both cases, testing would have been performed by exclusion testing using 
linkage analysis, as the parents were at 50% risk of having inherited HD and had not been through 
the predictive HD testing process. Both fetuses were at 25% risk of having inherited the gene for 
HD, and both couples chose to continue their pregnancies. The other three couples chose to have 
prenatal HD testing and included an affected female parent and two affected male parents. For 
these three couples who decided to continue with HD prenatal testing, tests were done by chorionic 
villus sampling (CVS). Three of the seven fetuses (including a set of twins) tested positive for HD 
using direct mutation testing. Both couples chose to terminate their affected pregnancies. There 
were four negative results done by direct mutation testing, including one fetus which tested 
negative for HD but had a karyotype of 47, XXX. All of these pregnancies were continued.   
 
 
 
 
3.5 COMPARISON OF INDIVIDUALS HAVING PREDICTIVE AND 
DIAGNOSTIC TESTS FOR HD 
 
This section compares the characteristics of individuals who had diagnostic and predictive testing 
for HD.  
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3.6.1 Comparison of the characteristics of individuals in the diagnostic HD testing group to 
those in the predictive HD testing group.  
 
Table 3-10: Comparison of characteristics of the individuals for whom diagnostic HD testing was 
requested to those who requested predictive counselling for HD between 1998 and 2006.  
 
 Predictive Diagnostic  
 Total        (%) Total           (%) p-valuea 
Gender  
   Female 38             (66.7) 115               (52) p=0.045* 
   Male 19             (33.3) 105            (47.5) 
   Unknown 0                    (0) 1                  (0.5)  
 
Ethnicity  
   White 52             (91.2) 106               (48) 
p<0.001*    Black 2                 (3.5) 93                 (42) 
   Indian 1                 (1.8) 4                  (1.8) 
   Mixed Ancestry 2                 (3.5) 11                   (5) 
   Unknown 0 7                  (3.2)   
 
Relationship Status 
   Not in relationship                     16             (28.1) 25             (11.3) p=0.85 
   In a relationship/Married   40             (70.2) 68             (30.8) 
   Unknown   1                 (1.7) 128           (57.9)  
 
Employment Status 
   Employed  42             (73.7) 30             (13.6) p<0.001* 
   Not employed   13             (22.8)                           36            (16.3) 
   Unknown  2                 (3.5) 155           (70.1)  
 
Number of Children 
   No children  31             (54.4) 24             (10.8) p<0.001* 
   One or more children   25             (43.9) 70             (31.7) 
   Unknown  1                 (1.7) 127           (57.5)  
 
Age 
   Median (SD) 30 years (SD±8.88) 49 years (SD±15.38) p<0.001* 
a p-value is calculated using Fisher’s exact test and is a comparison between the known variables only 
* Significant 
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When comparing the characteristics of the individuals who had diagnostic testing for HD to those 
who had predictive testing and/or predictive genetic counselling for HD, as shown in Table 3-10, 
the following were found to be significantly different between the two groups (unknowns were 
excluded from the calculations in all cases): 
 
Gender (p=0.045): In the HD predictive testing group, there were significantly more females 
requesting testing than males, compared to the diagnostic HD testing group, where the number of 
males and females who were tested was similar.  
 
Ethnicity (p<0.001): More white individuals requested predictive testing for HD than any other 
ethnic group whereas in the diagnostic testing group, the numbers of white and black individuals 
for whom HD testing was requested were similar. The ratio of white to black individuals in the HD 
predictive group (26:1) is much greater than the ratio of white to black individuals in the HD 
diagnostic group (1.1:1). In all ethnic groups, more individuals had diagnostic testing than 
predictive testing, but this was particularly obvious in the black population group.  
 
Employment status (p<0.001): Significantly more individuals in the HD predictive testing group 
were employed compared to the HD diagnostic testing group. In the predictive testing group, 
73.3% of individuals were employed while of those whose employment status was known in the 
diagnostic testing group, 45% were employed. Employment status was known for all but 3.5% of 
individuals in the predictive testing group, but was unknown for 70.1% of individuals in the 
diagnostic testing group.  
 
Number of children (p<0.001): Significantly more individuals in the HD diagnostic testing group 
had one or more children compared to the HD predictive testing group. However, the number of 
children was unknown for 57.5% of individuals in the HD diagnostic testing group, while this was 
unknown for only 1.7% of individuals in the HD predictive testing group.  
 
Age (p<0.001): The median age (30 years) of the individuals who requested HD predictive testing 
was significantly lower that the median age (49 years) of individuals for whom HD diagnostic 
testing was requested.  
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3.6 COMPARISON OF RESULTS FROM THIS STUDY AND THOSE OF A 
STUDY BY Kromberg et al. (1999) 
 
One of the aims of the study was to compare the number of patients seen and the patient 
characteristics observed in this study (1998 to 2006 – 9 years) to the results obtained in a previous 
study done by Kromberg et al. (1999) to identify trends over time. Kromberg et al. (1999) studied 
the utilization of predictive, prenatal and diagnostic testing for HD in Johannesburg in the Division 
between 1975 and 1997 (22 years). Linkage analysis became available in the Division in 1989, and 
was used for predictive and prenatal HD testing. Samples for HD diagnostic testing were sent to 
the University of Cape Town for direct mutation analysis from 1994 until 2001 when direct 
mutation analysis became available at the Division for diagnostic, predictive and prenatal HD 
testing.   
 
3.6.1 Number of predictive and diagnostic HD tests done during the two different study 
periods 
 
Table 3-11: Number and percentage of patients who had diagnostic and predictive testing for HD in 
this study and in the Kromberg et al. (1999) study.  
 
 This study  
(1998-2006) 
Kromberg et al. (1999) 
(1975-1997) 
p-value 
Diagnostic 221   (79.5%) 52    (55.9%) p<0.001 
 Predictive 57     (20.5%) 41    (44.1%) 
Total 278 93  
 
 
As seen in Table 3-11, almost 80% of tests completed between 1998 and 2006 were diagnostic HD 
tests, whereas diagnostic HD tests made up about 56% of all tests done between 1975 and 1997. 
The percentage of HD predictive tests decreased proportionately between the two studies. HD 
diagnostic tests made up significantly more (p<0.001; Fisher’s exact test) of the total number of 
HD tests requested in this study compared to that in the Kromberg et al. (1999) study. 
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3.6.2 Number of tests done per year during the Kromberg et al. (1999) study and the 
number done per year during this study 
 
The Kromberg et al. (1999) study looked at patient numbers and characteristics over 22 years – 
from 1975 to 1997, while this study looked at a 9 year period – from 1998 to 2006. When 
calculating the average number of tests done per year, the year when testing first became available 
was taken into account. The number of HD diagnostic tests could not be calculated over a 22 year 
period, as diagnostic testing for HD could only be done from 1994, when the HD gene was cloned 
and direct mutation testing could be offered. This resulted in HD diagnostic tests only being done 
during a four year period during the Kromberg et al. (1999) study. For predictive and prenatal HD 
testing linkage analysis became available in 1989, so tests per year were calculated over a 9 year 
period (1989-1997). The average number of tests done per year in each of the two studies is shown 
below in Table 3-12.   
 
Table 3-12: The average number of diagnostic, predictive and prenatal HD tests done per year from 
the time testing became available during the Kromberg et al. (1999) study. Also shown is the average 
number of diagnostic, predictive and prenatal HD tests done per year during the 9 year time period 
of this study. Direct mutation testing for HD was only available from 1994.  
 
 This study – 9 years Kromberg et al. (1999) – 22 years 
 
Number of 
tests 
Number of  
tests/year 
Number 
of tests 
Number of years 
during which testing 
was available 
Number of  
tests/year 
Diagnostic 221 24.56 52 4 13.00 a 
Predictive 57 6.33 41 9 4.56  b 
Prenatal 9 1.00 10 9 1.11 b 
a As direct mutation analysis only became available in 1994, number of HD diagnostic tests per year for the 
Kromberg et al. (1999) study was calculated over a 4 year period (1994-1997). 
b As linkage analysis only became available in 1989, the number of HD predictive tests per year and the 
number of HD prenatal tests per year for the Kromberg et al. (1999) study were calculated over a 9 year 
period (1989-1997). 
 
More HD diagnostic and predictive tests were done per year during the 9-year period analysed in 
this study compared to the number done per year when testing was available during the Kromberg 
et al. (1999) study. The number of prenatal HD tests done per year has remained low and 
consistent.  
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3.6.3 Comparison of HD diagnostic testing between the two studies with regard to ethnicity 
and test result 
 
The study by Kromberg et al. (1999) showed HD diagnostic testing results by ethnicity 
(white/black) and by test result (positive/negative), so those characteristics were compared to the 
ethnicity and test results obtained in this study, as shown in Table 3-13. 
 
Table 3-13: Summary of the number of HD diagnostic tests completed by white and black individuals 
in this study compared to the number completed in the Kromberg et al. (1999) study. 
 
    This study Kromberg et al. (1999) p-value 
Number of tests requested    221 52  
Number of tests completed    208     (94.1%) 52       (100%)  
Tests 
completed 
Whites 
Positive    62       (61.4%) 8        (47.1%) 
p=0.29 
Negative    39       (38.6%) 9        (52.9%) 
Blacks 
Positive    40       (46.5%) 11         (55%) 
p=0.62 
Negative    46       (53.5%) 9           (45%) 
 
There was no significant difference between the two studies with regard to the percentage of 
positive and negative HD results obtained in either the white (p=0.29, Fisher’s exact test) or the 
black population (p=0.62; Fisher’s exact test).  
 
Table 3-14: Summary of the total number of white and black individuals who had HD diagnostic 
testing in this study compared to the Kromberg et al. (1999) study. 
 
 
   This study Kromberg et al. (1999) p-value 
Total number of whites who had 
HD diagnostic testing 
   101    (54.0%)    17     (45.9%)    
p=0.38 
 Total number of blacks who had 
HD diagnostic testing 
   86      (46.0%)    20     (54.1%) 
 
No significant difference was found between the percentage of white individuals and the 
percentage of black individuals who had HD diagnostic testing during the Kromberg et al. (1999) 
study compared to this study, as summarized in Table 3-14 (p=0.38; Fisher’s exact test). 
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3.6.4 Comparison of predictive testing for HD between the two studies with regard to 
gender 
 
Results of the Kromberg et al. (1999) study showed HD predictive testing results by gender.  
 
Table 3-15: Summary of the number of HD predictive tests completed by males and females in this 
study compared to the number completed in the Kromberg et al. (1999) study. 
 
    This Study Kromberg et al. (1999)  p-value 
Number of tests requested    57 41 
p=0.51 
Number of tests completed    38       (66.7%) 30          (73%) 
Tests 
completed 
Males    15       (39.5%) 13       (43.3%)   
p=0.81 
Females    23       (60.5%)  17       (56.7%) 
 
There was no significant difference between the number of HD predictive tests completed in this 
study and the number completed in the previous Kromberg et al. (1999) study (p=0.51), as shown 
in Table 3-15. There was also no significant difference between the number of HD predictive tests 
completed by males and females in the two studies (p=0.81), but in both studies there were more 
female patients than male patients. 
 
3.6.5 Comparison between this study and the Kromberg et al. (1999) study with regard to 
the number of HD prenatal tests done and the test results obtained  
 
 
Table 3-16: The number of prenatal tests requested during this study and the Kromberg et al. (1999) 
study as well as number of positive and negative results recorded during each study.  
 
       This study Kromberg et al. (1999) 
Number of tests requested       9       (5 couples) 10       (7 couples) 
Number of tests completed       7       (77.8%) 10       (100%) 
Results 
Positive       3       (42.9%) 3         (30%) 
Negative       4       (57.1%) 7         (70%) 
 
 
Results of the Kromberg et al. (1999) study showed HD prenatal testing results only (positive or 
negative for HD), and did not characterise the patients further. In both studies the number of 
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prenatal tests requested was small, as shown in Table 3-16. No tests in this study were done using 
linkage analysis, while three tests in the Kromberg et al. (1999) study were performed using 
linkage analysis.   
 
In both studies, all of the couples who received a positive HD prenatal diagnosis chose to terminate 
the pregnancy. One couple in the previous study received a risk of 48% of the fetus having 
inherited HD based on exclusion testing and chose to continue the pregnancy.  
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4 DISCUSSION 
 
4.1 NUMBER OF DIAGNOSTIC, PREDICTIVE AND PRENATAL TESTS 
FOR HD REQUESTED BETWEEN 1998 AND 2006 
 
The majority of HD tests (77%) requested between January 1998 and December 2006 at the 
Division were diagnostic tests. Predictive HD tests made up 20% of the study sample, while only 
3% of the sample comprised prenatal HD tests.  
 
4.1.1 Utilization of the HD diagnostic testing service at the Division 
 
There has been an overall increase in the number of HD diagnostic tests requested since 1998, 
although the number decreased between 2005 and 2006. One reason for the increase in the number 
of HD diagnostic tests may be a greater recognition of symptoms suggestive of HD by doctors and 
specialists. This is an important reason, as most HD diagnostic tests are requested by specialists 
and doctors outside of the Division. There has possibly also been an increased awareness of the 
HD diagnostic testing service, particularly HDL2 testing which was set up in 2004 as part of a 
research project. HDL2 testing is now routinely done in the Division. Changes in the number of 
HD diagnostic tests done each year may also reflect changes within the Neurology Departments 
that refer patients to the Division. This may include, for example, the loss of staff that were aware 
of and utilized the services offered by the Division, thereby decreasing the number of HD 
diagnostic tests done, or the joining of new staff that have a good knowledge of HD and the testing 
services available for this disorder, leading to increased referrals from these professionals and an 
increase in the number of HD diagnostic tests done in the Division.  
 
4.1.2 Utilization of the HD predictive testing service at the Division 
 
There has been a general increase in the number of HD predictive tests requested since 1998, 
though the overall number of patients tested each year has remained relatively small. Between 
1998 and 2002 an average of 3.8 HD predictive tests were done per year but in the last four years 
of this study (2003-2006) this has increased to an average of 9.5 per year, peaking at 11 patients in 
2005. The upward trend in numbers could be due to an increase in the number of individuals who 
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have become aware of the HD predictive testing service, possibly from relatives, although we have 
no evidence for this. It seems likely that the number of HD predictive patients seen would increase 
when the number of diagnostic tests increases due to family members becoming aware of the 
condition in their family. However, the number of predictive tests done for HD has not increased 
proportionately, possibly due to poor referrals for HD genetic counselling by medical 
professionals.   
 
4.1.3 Utilization of HD diagnostic testing compared to HD predictive testing 
 
The number of HD diagnostic tests requested each year has remained higher than the number of 
HD predictive tests. One reason for this may be that HD predictive testing is a self-selection 
process as opposed to HD diagnostic testing where doctors can send samples straight to the 
laboratory for testing. It may also be that there is limited awareness of the HD predictive testing 
services offered at the Division or it could be due to a lack of awareness by individuals that they 
are at risk of having inherited HD. Evers-Kiebooms et al (1989) and Evers-Kiebooms, Nys, Harper 
et al (2002) suggested that fewer HD predictive tests may be requested out of fear of finding out 
one’s status, a perceived inability to deal with a positive result or due to the lack of cure for HD 
(Taylor 2004). Although uptake of HD predictive testing was not determined in this study, as the 
number of at-risk individuals was not known, previous studies have shown various HD predictive 
testing uptake rates ranging from 4% to 24% (Reviewed in Richards and Rea 2005). A study by 
Creighton, Almqvist, MacGregor et al (2003) determined the rate of uptake of predictive testing 
for HD in Canada to be approximately 18%, while a study by Maat-Kievet, Vegter-van der Vlis, 
Zoeteweij (2000) showed an uptake rate of 24% in the Netherlands. Uptake rates have been found 
to be much lower in Germany, Austria and Switzerland, estimated at below 3% to 4% (Laccone, 
Engel, Holinski-Feder et al. 1999). These researchers determined the uptake rates in their studies 
by using national or local registers containing the details of individuals with HD. No such register 
is available in South Africa so a calculation of the uptake rate could not be attempted in this study. 
Analysis of the number of at-risk individuals who request predictive testing for HD, out of the total 
number of at-risk individuals known to the Division, could possibly have been estimated by 
looking at the pedigrees of affected individuals. However, data were often limited as many 
individuals who had diagnostic HD testing in the Division did not have genetic counselling. 
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4.1.4 Utilization of HD prenatal testing at the Division 
 
The uptake of HD prenatal testing was low, with only 9 prenatal tests being requested between 
1998 and 2006. Between one and three tests were requested each year, with no tests being 
requested between 2003 and 2006. This is interesting, as it was during these four years (2003-
2006) that the number of HD predictive and diagnostic tests requested increased, so it would be 
expected that more HD prenatal tests would have been requested.  
 
A low uptake rate of HD prenatal testing has been found in other studies, with uptake rates 
estimated to be between 8% and 18% (reviewed in (Richards and Rea 2005; Robins Wahlin 2007). 
The low uptake of HD prenatal testing may be due to a lack of knowledge about this option 
amongst patients who do not receive genetic counselling for HD. Another factor may be that 
individuals choose not to have HD prenatal testing due to an objection to termination of an affected 
pregnancy (Maat-Kievit et al. 2000; Evers-Kiebooms et al. 2002; Richards and Rea 2005). It was 
also noted from this study that “aiding in reproductive decision making” was given as a reason for 
undergoing HD predictive testing by only four patients out of the 53 individuals (5%) who had HD 
predictive testing between 1998 and 2006. This suggests that most individuals who have predictive 
testing for HD may not consider HD prenatal testing to be very important, may hold hope for 
future cures or may decide not to have children if they test positive for HD. However, two couples 
in this study had more than one pregnancy tested for HD, which suggests that some individuals 
find the service beneficial. 
 
HD prenatal testing uptake may also be low because HD is a dominant disorder, and therefore 
approximately 50% of at-risk individuals are expected to test negative. These individuals would no 
longer require prenatal testing for HD. In this study 59% of patients tested negative for HD which 
means that they would no longer need to consider prenatal diagnosis. Another reason may be that 
the individuals testing positive for HD (both symptomatic and asymptomatic individuals) may 
already have children and may not be planning further pregnancies. Some studies have shown that 
individuals are less likely to have further pregnancies after receiving a positive HD predictive test 
result (Meissen et al. 1991; Maat-Kievit et al. 2000; Tibben 2007). In this study, 44.1% of patients 
who had HD predictive testing had at least one child, while 52.5% did not. Individuals who test 
positive for HD may also consider other reproductive options (such as adoption, sperm/egg donors 
or PGD) and would then not require prenatal testing for HD. A study by Evers-Kiebooms et al. 
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(2002) found that a common reason for individuals declining HD prenatal testing was the hope of a 
future cure for their children as well as a fear of the tests used for prenatal diagnosis (CVS or 
amniocentesis). 
 
4.2 GENETIC COUNSELLING FOR HD 
 
Genetic counselling is not a requirement for those having HD diagnostic testing, while all 
individuals who request predictive HD testing need to attend a genetic counselling session. This is 
one reason why only 27.6% of individuals for whom HD diagnostic testing was requested received 
genetic counselling. Also, many of these diagnostic requests come from doctors who want to 
confirm a diagnosis of HD in their patient. Although the laboratory results sent to the doctor have 
contact details for the genetic counselling service at the Division, doctors may not pass this 
information onto their patients and inform family members of their risks, possibly underestimating 
the value of genetic counselling for families. Samples for diagnostic HD testing are also sent in 
from all over South Africa, so the individuals being tested may not have easy access to the genetic 
counselling service in Johannesburg. It would be beneficial for HD diagnostic patients and their 
families to attend a genetic counselling session to learn more about the condition and about the at-
risk status of other family members (Bernhardt, Biesecker and Mastromarino 2000). It would 
therefore be appropriate for all individuals testing positive for HD diagnostically, as well as their 
families, to be offered genetic counselling.   
 
4.3 DEMOGRAPHICS OF PATIENTS WHO HAD DIAGNOSTIC, 
PREDICTIVE AND/OR PRENATAL TESTING FOR HD 
 
4.3.1 Demographics of individuals who had diagnostic testing for HD 
 
4.3.1.1 Gender 
 
There was no significant difference between the number of males and females in the HD 
diagnostic testing group (p=0.71; Fisher’s exact test) and gender did not impact on the likelihood 
of receiving either a positive result (HD1 or HDL2) or a negative result (p=0.80; Fisher’s exact 
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test). This was expected, as HD is a dominantly inherited disorder which affects males and females 
equally. Other researchers have also found a ratio of approximately 1:1 male: female in their 
studies (Harper 1996; Creighton et al. 2003) 
 
4.3.1.2 Age, relationship status, number of children, and employment status  
 
The majority of individuals for whom diagnostic HD testing was requested were between the ages 
of 40-49 years (18.7%) and 50-59 years (21.1%) (Table 3-6). This was expected as these are the 
age ranges during which HD symptoms typically present (Tibben 2007). HD symptoms usually 
start in the third or fourth decade of life (Young 2003; Landles and Bates 2004), so by the late 40’s 
and early 50’s, symptoms may have become severe and easier to detect, increasing the number of 
individuals tested diagnostically for HD.  
 
The white individuals in this study who tested positive for HD were slightly younger (median 48 
years) than the black (median 52 years) and mixed ancestry (median 50 years) individuals. Indian 
individuals who tested positive for HD had a median age of 31 years. The younger age of diagnosis 
of Indian individuals may suggest that they develop symptoms earlier, but the sample size (4 
seemingly unrelated individuals) is too small to make assumptions about HD in this ethnic group 
as a whole. With regard to the later age of diagnosis of black individuals with HD, this may be due 
to the misconception that HD is rare in the black population group (Joubert and Botha 1988), 
causing some clinicians to be reluctant to consider it as a diagnosis. However, when an individual 
in a family is diagnosed with HD, it may enable other family members to be diagnosed earlier. 
 
Although 13 individuals were under the age of 20 at the time of the test, only 1 of these individuals 
(7.7%) tested positive for HD. This was expected as juvenile HD is estimated to have a prevalence 
rate of about 4% in the South African white HD population and up to about 15.7% in the mixed 
ancestry HD population (Hayden et al. 1982). Although this makes juvenile HD relatively rare, 
these rates are much higher than those found elsewhere in the world, with a study by Laccone et al. 
(1999) reporting a 0.9% prevalence rate of juvenile HD in the German, Austrian and Swiss 
populations.  
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In the HD diagnostic testing group, more individuals were in a relationship (30.8%) than not 
(11.3%), and more individuals had children (31.7%) than did not (10.8%). This was expected due 
to the age of the individuals in this group, as more would be expected to be in a relationship and 
have had children by their 40’s and 50’s. However, the results may not accurately reflect what is 
happening in the HD diagnostic testing group, as the relationship status and number of children 
was unknown for the majority of individuals (57.9% and 57.5% respectively) in this group. This 
information is not requested on the test request forms and is usually only known if the patient 
receives genetic counselling. Not knowing the number of children of HD positive individuals 
means that this group, who are at 50% risk of having inherited HD from their affected parent, 
cannot be made aware of their risks (by HD information pamphlets/letters sent to them, for 
example) and offered genetic counselling as their details are not known.  
 
There was no significant difference (p=0.16) between the number of individuals in the HD 
diagnostic testing group who were known to be employed and the number known to be 
unemployed compared to the general South African population, where 58.4% of individuals are 
employed and 41.6% are unemployed (Statistics South Africa 2001). We would expect more 
unemployed individuals in the diagnostic testing group as they may be more likely to have had to 
stop working because of their HD symptoms. However, for a large proportion of the diagnostic 
testing group (70.1%) in this study, employment status was unknown. Harper (1996) reported that 
many individuals may be able to work up to 5 years after the start of symptoms, with a few 
maintaining their ability to work 10 years after symptoms start. It is often after the start of more 
severe symptoms that patients would present to a medical professional, when they have already 
had to stop working. It is possible that, in South Africa, the effect of HD on the ability of affected 
individuals to work may be obscured by the unemployment rate, as many of these individuals may 
be unemployed due to the unavailability of jobs, rather than due to HD symptoms preventing them 
from working. 
 
4.3.1.3 Ethnicity 
 
With regard to ethnicity, a smaller proportion of black individuals underwent diagnostic testing for 
HD than would be expected based on population data from the 2001 South African Census. Also, a 
larger proportion of white individuals had HD diagnostic testing than was expected based on the 
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2001 South African Census data (Table 3-2). This may be due to a lack of awareness of this 
service among professionals treating black individuals with HD or a lack of consideration of HD as 
a diagnosis in this population group possibly due to a misconception that HD is rare in black 
individuals (Joubert and Botha 1988).  
 
Another explanation is that HD may be less prevalent in the black population group. HD was first 
estimated to have a prevalence of 0.01 per 100,000 in the black and mixed ancestry populations by 
Hayden et al (1982), although this is now thought to be an underestimate. Other studies since then 
have provided HD prevalence rates of between 0.97 per 100,000 and 6.37 per 100,000 in the South 
African black population (Reviewed in Silber, Kromberg, Temlett et al. 1998). The prevalence of 
HD in the South African mixed ancestry population, however, seems to be similar to the 
prevalence in the South African white population (approximately 2.2 per 100,000) (Hayden, 
MacGregor and Beighton 1980) , with both HD1 and HDL2 occurring in the mixed ancestry 
group. 
 
4.3.2 Demographics of patients who requested predictive testing for HD 
 
4.3.2.1 Gender 
 
Significantly more females requested HD predictive testing than males (p=0.02; Fisher’s exact 
test). This has been found in numerous other studies (Tyler, Ball and Craufurd 1992; Harper et al. 
2000; Maat-Kievit et al. 2000; Creighton et al. 2003; Richards and Rea 2005). Suggestions as to 
the reason for this include women being more likely to face health issues in themselves, as well as 
women’s more active role in reproductive decision-making and childcare. Men may be less likely 
to want to deal with the emotional issues involved in predictive testing for HD and in reproductive 
decision-making (Harper et al. 2000; Maat-Kievit et al. 2000; Richards and Rea 2005) 
 
4.3.2.2 Age, relationship status, employment status and number of children 
 
Most individuals requesting predictive testing for HD were between the ages of 20 and 29 years 
(42.1%), followed by those in the 30-39 year age group (35.1) (Table 3-7). The age range seen 
Discussion 
 58
here is similar to that found in studies by Tyler et al. (1992) and Creighton et al. (2003). These are 
the ages when individuals may start thinking about their future such as planning relationships, 
careers and/or finances and may want to know their HD status for this reason (Tibben 2007). Few 
individuals under the age of 20 would be expected to request predictive testing for HD as 
individuals usually need to be at least 18 years of age to enter the HD predictive testing program. 
Also, few individuals over the age of 40 would be expected to request predictive testing for HD, as 
at-risk individuals over this age are likely to have started showing symptoms already, if they have 
inherited the mutation, as symptoms of HD generally start in the 3rd or 4th decade of life (Young 
2003; Landles and Bates 2004) 
 
Most individuals in the HD predictive testing group were employed and in a relationship (73.7% 
and 70.2% respectively). This may be reflective of the age of the individuals requesting HD 
predictive testing (median 30 years), as many would be expected to have entered the working 
environment and be in a relationship by this time. Although not significantly different from the 
58.4% employment rate among the general South African population (p=0.07) (Statistics South 
Africa 2001), the higher employment rate of 73.7% seen in the HD predictive testing group may 
partly be due to the majority of individuals in the predictive testing group (91.2%) being white. 
Statistics from the South African Census 2001 show that out of the 41.6% of unemployed South 
Africans, only 6.9% are white, so in a mostly-white HD predictive testing group, a higher rate of 
employment can probably be expected, compared to the general South African population where 
9.6% of individuals are white. 
 
About 55% of individuals in the HD predictive testing group had children, while approximately 
45% of individuals did not. These results were similar to a Belgian study by Decruyenaere et al. 
(2005) where approximately 47% of individuals had no children. Other studies, however, have 
found that more individuals have no children than have children. A study by Maat-Kievit et al. 
(2000) in the Netherlands, found that 56% of the individuals who had predictive testing for HD 
had no children, while 64% of individuals in a study by van der Steenstraten et al. (1994), also in 
the Netherlands, had no children. Richards and Rea (2006) looked at an Australian HD predictive 
testing group and found that 53% of these individuals had no children.  
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4.3.2.3 Ethnicity 
 
With regard to ethnicity, most of the individuals who requested predictive HD testing (91.2%) 
were white, with few black, Indian and mixed ancestry individuals requesting testing. The 
proportion of whites undergoing predictive testing (91.2%) is much higher than the proportion of 
whites expected to undergo predictive testing for HD (9.6%), based on South Africa population 
census data (Statistics South Africa 2001).  
 
Reasons for this could include an increased awareness of and access to the HD predictive testing 
service by white individuals compared to those of other ethnicities. A study in the United States of 
America (USA) into the uptake of predictive testing for breast cancer found that less than 29% of 
at-risk black individuals were aware of genetic testing, compared to almost 40% of at-risk white 
individuals (Peters, Rose and Armstrong 2004). If affected black individuals are not adequately 
referred for HD genetic counselling, their relatives would not be aware of their at-risk status or of 
the services offered in the Division.  
 
Another American study also showed that black individuals were less likely than white individuals 
to undergo genetic counselling and/or testing for the breast cancer susceptibility genes BRCA1 and 
BRCA2 (Armstrong, Micco, Carney et al. 2005). The authors suggest that this may be due to 
“health care related-distrust” which has been found to be higher among black individuals than 
white individuals in the USA (Armstrong et al. 2005). It is possible that this is also the case in 
South Africa, and may be one of the reasons fewer black individuals request predictive testing for 
HD compared to white individuals. A study by Ashton, Haidet, Paterniti et al. (2003) in the USA, 
also showed that a greater proportion of white than black individuals utilised health services. They 
suggested that this may be due to a bias on the part of the doctors treating black individuals, 
resulting in them being less likely to refer black individuals to other health care professionals. The 
lower proportion of black individuals utilizing health services in the USA may also be due to the 
preferences of the black individuals not to seek treatment, or may be due to difficulties in 
communication and decision-making between the patient and the health care professional (Ashton 
et al. 2003).  
 
It is also possible that black individuals are seeking help from traditional healers for HD rather 
than attending a hospital or clinic. A study by Ngoma, Prince and Mann (2003) involving a Swahili 
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population in Tanzania, showed that 48% of individuals visiting traditional healers did so for 
common mental disorders, compared to 24% of individuals visiting primary health clinics. 
Individuals may seek  help from traditional healers owing to their availability compared to primary 
health clinics, or due to cultural beliefs, such as mental illness being the result of ancestral or evil 
spirits being used to inflict misfortune (Ngoma et al. 2003). It is possible that in South Africa, as in 
Tanzania, black individuals who are experiencing psychiatric symptoms, such as those associated 
with HD, are not seeking medical care from primary health centres, but rather from traditional 
healers, which may be one reason for the small number of black individuals in the HD predictive 
testing group.  
 
Another reason for the small number of black individuals requested HD predictive testing, may be 
that HD is possibly less prevalent in the black population compared to the white population 
(Hayden, MacGregor and Beighton 1980; Hayden et al. 1982; Silber et al. 1998). 
 
4.3.2.4 Demographics of the individuals who completed the HD predictive testing process and 
those who did not complete it 
 
Gender, ethnicity, relationship status, employment status and number of children were not found to 
significantly influence whether or not the HD predictive testing process was completed (Refer to 
Appendix E). This is in keeping with a study in the Netherlands by Maat-Kievit (2000) who found 
no difference with regard to age, gender and number of children between the individuals who 
completed the HD predictive testing program and those who did not complete it.  
 
There may be other factors which influence the decision to complete the HD predictive testing 
process such as fear about the test result and its meaning for the individual, fear of discrimination 
and stigmatization (regarding insurance, medical cover, job opportunities, etc), financial issues, 
family influence and external factors out of their control (Taylor 2004). A study by van der 
Steenstraten, Tibben, Roos et al. (1994) in the Netherlands found that the most common reason for 
not participating in the HD predictive program was “fear of confirmation of getting HD”, followed 
by “fear of adverse effects after receiving an increased risk”. Other common reasons given were 
that the individuals felt they were coping well with their current uncertainty about whether or not 
they would develop HD, they did not want to shatter their hope or that they did not want to have 
testing when there is currently no treatment available for HD (van der Steenstraten et al. 1994). 
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However, reasons individuals did not complete the HD predictive testing process were not assessed 
in this study.  
 
 
4.3.3 Demographics of the individuals for whom HD diagnostic testing was requested 
compared to the demographics of the individuals who requested HD predictive testing 
 
Significantly more females than males requested HD predictive testing, while an approximately 
equal number of males and females requested HD diagnostic testing. This is reflective of the 
expected 1:1 male to female ratio in the HD diagnostic group due to the autosomal dominant 
nature of HD. However, this does not hold true for HD predictive testing, as this is a self-selection 
process, where females seem to be more likely than males to request testing, for reasons discussed 
in section 4.3.2.1. 
 
The median age of individuals in the HD predictive testing group was significantly lower (30 
years) than the median age of individuals in the HD diagnostic group (49 years) (p=0.03; Fisher’s 
exact test). This was not surprising, as it was expected that individuals who request HD predictive 
testing would be younger than those in the HD diagnostic testing group, where individuals have 
already started showing symptoms of HD. As stated earlier, symptoms of HD generally start in the 
3rd or 4th decade of life (Young 2003; Landles and Bates 2004). 
 
The older age of individuals in the HD diagnostic group may account for the lower rate of 
employment seen in the HD diagnostic testing group than in the HD predictive testing group, 
possibly due to these individuals having symptoms of HD. The lower rate of employment seen in 
this group may also be due to the larger percentage of black individuals in the diagnostic testing 
group (42%), compared to the predictive testing group (3.5%). Statistics available from the 2001 
South African Census show that 31.1% of black individuals in South Africa are unemployed 
compared to 6.9% of white individuals (Statistics South Africa, 2001). The higher unemployment 
rate seen in the HD diagnostic testing group may be reflective of the general unemployment rate 
among the black population in South Africa, as this population group is better represented in the 
HD diagnostic testing group than the HD predictive testing group. Age may also be the reason why 
more individuals in the HD diagnostic group had children compared to individuals in the HD 
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predictive testing group (p<0.001; Fisher’s exact test). Relationship status was similar in both the 
HD diagnostic and predictive testing groups, with most individuals being in a relationship.  
 
In both the HD diagnostic and predictive testing groups, more white individuals had testing than 
was expected based on the data from the South African 200 Census, but this was particularly 
obvious in the HD predictive testing group. As discussed earlier, this may be due to lack of 
awareness of HD in population groups other than the white population or may be due to a 
decreased incidence of HD in other population groups (reviewed in Silber et al. 1998) or may be 
due to cultural factors, as discussed in section 4.3.2.3. 
 
4.3.4 Demographics of the individuals who requested prenatal testing for HD 
 
All individuals in this study who requested prenatal testing for HD were white and in a 
relationship. Most individuals requesting prenatal counselling and/or testing for HD were between 
the ages of 24 and 34, with one individual being over the age 40. Three of the individuals who 
requested HD prenatal testing were female and two were male. Other studies have found that more 
females than males request prenatal testing for HD, but the sample size of this study is too small to 
make comparisons (Richards and Rea, 2005). It has been suggested that males may be reluctant to 
ask their female partners to undergo prenatal testing and consider termination of pregnancy 
(Richards and Rea, 2005). 
 
All 7 tests that were completed were for individuals who already knew their status. The two 
individuals who were at 50% risk of having inherited HD and would have needed exclusion testing 
opted not to have prenatal HD testing. This was also seen in a study by Richards and Rea (2005) 
where individuals preferred to know their own status before testing a pregnancy. Individuals may 
prefer to be sure about whether or not their child is actually at risk of having inherited HD before 
placing the pregnancy at risk by undergoing amniocentesis or CVS.  
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4.4 TEST COMPLETION, RESULTS AND MOTIVATIONS 
 
4.4.1 Diagnostic testing for HD 
4.4.1.1 Test completion 
 
In this study, 13 of the 227 (5.7%) diagnostic tests requested were not completed. The most 
common reason for this (46.2% of uncompleted cases) was blood being sent in the incorrect tube, 
so it could not be processed. This suggests that in some cases doctors may not be aware of the 
correct procedures required by the Division when sending in samples for HD diagnostic testing.  
 
4.4.1.2 HD diagnostic test results 
 
All individuals who had diagnostic testing for HD would have had symptoms suggestive of a 
neurodegenerative disorder, though these symptoms may not have been entirely suggestive of HD. 
A review of black HD negative individuals by Professor Amanda Krause, Head of the Clinical 
Section at the Division showed that only a few of these HD negative individuals actually had 
symptoms suggestive of HD (A. Krause, personal communication, November 2007). This may 
account for the approximately 45% of individuals in the HD diagnostic testing group whose HD 
tests results were negative.  
 
HD symptoms may also closely resemble other disorders such as chorea-acanthocytosis and 
spinocerebellar ataxia 17 and may be a differential diagnosis (Gold, Shifteh, Bello et al. 2006; 
Schneider, van de Warrenburg, Hughes et al. 2006). There is also the small possibility that a third, 
as yet unidentified, locus may be the cause of HD in some of the individuals who tested negative 
for HD1 and HDL2.  
 
Receiving either a positive result (HD1 or HDL2) or a negative HD result appeared to be 
dependent on ethnicity (p<0.001; Fishers exact test). Individuals of white, mixed or Indian 
ancestry were more likely to test positive for HD than negative, while black individuals were 
equally likely to test positive or negative for HD. This may suggest increased accuracy in the 
identification of symptoms of HD in the white, mixed ancestry and Indian population groups than 
in the black population group. It may also suggest that disorders mimicking HD are less common 
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in population groups other than the black population, so individuals from the white, mixed ancestry 
or Indian population groups who present with symptoms suggestive of HD are more likely to have 
HD than some other condition. 
 
In the HD diagnostic testing group, 35% of black individuals who tested positive for HD were 
positive for HDL2. This result is similar to information obtained from Prof. Amanda Krause, Head 
of the Clinical Section at the Division, that approximately one third of black South African HD 
patients have HDL2 (A. Krause, personal communication, November 2007). Approximately 43% 
of individuals of mixed ancestry who tested positive for HD were positive for HDL2, suggesting 
that HDL2 is almost as common as HD1 in this population group.  
 
Children of individuals testing positive for HD are at 50% risk of having inherited the disorder. 
The number of children was known for 64 of the 111 individuals (57.7%) in the diagnostic testing 
group who tested positive for HD1 or HDL2, and totalled 160 individuals. These individuals may 
or may not be aware of their risk of having inherited HD so it is important that these individuals 
are informed of this and have access to genetic counselling for HD. In August 2007 it was decided 
by the Division to attempt to do this by posting a HD newsletter to the last known address of 
individuals who tested positive for HD, providing them with support and information, as well as 
contact details for the genetic counselling unit at the Division. Also included was a form inviting 
individuals to update their contact details if they wished to receive further correspondence. Thirty-
three letters have been sent out to date, and 10 responses (all requesting further information) have 
been received so far.     
 
4.4.2 Predictive testing for HD 
 
4.4.2.1 Motivation of individuals in this study for requesting HD predictive testing 
 
The results show that 50.9% of individuals in this study who requested predictive testing for HD 
had one main reason for doing so, while some individuals had two or more reasons. The most 
common reason given was to decrease anxiety, which is similar to results of other studies (Evers-
Kiebooms et al. 2002). Knowing one’s status may help to relieve stress and enable the individual 
to think about their future to some extent (Robins Wahlin 2007). This is closely linked to the 
second most commonly given reason for finding out one’s status - planning for the future. In a 
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study by Lucas (1998), “planning for the future” was the most commonly given reason for entering 
the HD predictive testing process. Planning for the future usually involves financial planning to 
ensure enough money is available for care of an affected individual and for their family (Evers-
Kiebooms et al, 2002), looking for appropriate medical and life insurance plans, deciding on issues 
relating to relationships and reproduction and deciding on careers and employment. Lucas (1998) 
found that individuals considered planning for the future to include planning a family, making 
financial and residential decisions for the future, deciding whether to marry and/or making changes 
in their employment status. 
 
Only four of the individuals in this study cited “aiding in reproductive decision making” as one of 
their reasons for entering the HD predictive testing process. This is much lower than the rates 
given by other researchers such as Evers-Kiebooms et al. (2002) who reported that 38% of 
individuals requesting predictive testing gave “reproductive decision-making” as a main reason. 
The low rates reported in this study may be that many individuals in this study could have 
considered “aiding in reproductive decision-making” to be a way of “planning for the future”, as 
was seen in the study by Lucas (1998). Information regarding motivations for entering the 
predictive testing program were obtained from notes written in the patient’s genetic counselling 
file rather than by direct questioning, so it was not known what each individual considered to be 
part of “planning for the future” when providing this as their motivation. Another reason why 
“aiding in reproductive decision making” was only given as a motivation by four individuals, may 
be that many individuals in this study already had children (43.9%) and did not require the service. 
Other individuals may not have been concerned with child-bearing at that time. 
 
Only 12% of individuals in this study reported wanting to know their HD status to inform their 
children of their new risk. This is lower than the rate found by Evers-Kiebooms et al (2002) who 
reported that 28% of individuals in their study said they wanted to know their HD status to inform 
their children of their risks.  
 
4.4.2.2 HD predictive test completion  
 
Approximately 67% percent of individuals in this study who attended an initial genetic counselling 
session for HD predictive testing completed the process. A study by Mandich, Jacopini, Di Maria 
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et al. (1998) in Italy showed that more than half of the individuals who entered their predictive 
testing program withdrew after counselling once they had had time to contemplate what a positive 
HD test result may mean for them in their lives. Reasons for not entering the HD predictive 
program or not completing the HD predictive testing process may include fear of receiving an 
increased-risk result and not being able to cope with it, knowing there is no available treatment for 
the disorder, fear of the future and what will happen to them if the results show they will develop 
HD, fear of discrimination such as loss of insurance, the financial costs of completing the HD 
predictive testing program, and just preferring not to know (Reviewed in Maat-Kievit et al, 2000; 
Evers-Kiebooms et al, 2002). However, it is not easy to study the individuals who do not enter the 
HD predictive testing process, as it may be difficult to obtain contact details for them and, if 
contacted, these individuals may be reluctant and/or feel pressurised to participate in studies 
regarding HD. 
 
The median time taken to complete the HD predictive testing process was 125.5 days 
(approximately 4 months; SD±156.6). Time taken to complete the HD predictive testing process 
has not been reported in other studies, so comparative data are not available. The time taken to 
complete the process reflects the number of professionals who need to be seen before a result is 
given. Individuals who completed the program in a shorter time period may have been very 
anxious and have wanted to complete the process quickly while individuals who took longer may 
not have been ready to receive a result or may, like some of the individuals in this study, have 
lived in bordering countries or far away from Johannesburg, with transport problems hampering 
the process.  
 
4.4.2.3 Result of HD predictive testing 
 
Of the individuals who had predictive testing for HD, 39.5% tested positive (for HD1 or HDL2) 
while 60.5% tested negative. This did not differ significantly from the 50% positive rate (p=0.50; 
Fisher’s exact test) expected for autosomal dominant disorders, such as HD. Other studies have 
also shown an increased number of negative test results, although also not significantly increased, 
with a ratio of approximately 40% positive/60% negative (Benjamin, Adam, Wiggins et al. 1994; 
Almqvist et al. 1999; Harper et al. 2000; Maat-Kievit et al. 2000; Creighton et al. 2003). Maat-
Kievit et al. (2000) suggested that this may be due to the age range of individuals requesting 
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predictive testing (usually 30-39 years) which would reduce the age-related risk from 50% to 
between 47.6% and 42.5% because a percentage of individuals would have already started 
showing symptoms (Harper et al. 2000). They also suggest that the self-selection process for HD 
predictive testing may play a role. Individuals may feel they are asymptomatic and feel confident 
of receiving a negative result so request HD predictive testing. Alternatively, early cognitive 
symptoms in HD carriers may cause them to be less motivated to request predictive testing, 
thereby lowering the number of positive test results seen (Tyler et al, 1992; Maat-Kievit et al. 
2000). A larger study sample will be needed to confirm the apparent increased number of negative 
results seen in this and other studies.  
 
Only one individual tested positive for HDL2 in the predictive testing group. This is due to the 
small number of black (two) and mixed ancestry (two) individuals requesting HD predictive 
testing in this study. HDL2 has not been found to occur in white individuals and this population 
group made up the majority of the HD predictive testing group in this study.  
 
4.4.3 HD diagnostic testing compared to HD predictive testing with regards to test 
completion 
 
Most HD diagnostic tests were completed (94.7%), while only 66.7% of the individuals who 
attended a genetic counselling session regarding HD predictive testing completed the predictive 
testing process. This is due to the self-selection process involved in HD predictive testing, where 
individuals can chose whether or not to continue with the HD predictive protocol, while with HD 
diagnostic testing, samples are usually sent in by a doctor.  
 
4.4.4 Prenatal testing results 
  
Seven fetuses (including a set of twins) were tested for HD. Three fetuses tested positive for HD 
(including both twins) and these pregnancies were terminated. The other four pregnancies tested 
negative, and were continued. Individuals who choose to terminate an affected pregnancy may 
have decided they did not want to have a child who will eventually develop HD. Other studies 
have also found that individuals who have a pregnancy tested for HD choose to terminate the 
pregnancy if the fetus tests positive (Reviewed in Richards and Rea, 2005). 
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4.5 COMPARISON OF THE UTILIZATION OF HD TESTING SERVICES 
BETWEEN THIS STUDY AND THAT OF A PREVIOUS STUDY DONE 
BY Kromberg et al. (1999) 
 
4.5.1 Comparison between the two studies with regard to the utilization of the HD 
diagnostic testing service offered by the Division 
 
Compared to the Kromberg et al. (1999) study, there has been an increase in both the number of 
HD diagnostic tests done per year (from 13.00 per year to 24.56 per year), as well as the 
percentage of diagnostic tests out of all HD tests done. This may be due to an increased awareness 
of the service by medical professionals and an increased awareness of and diagnosis of HD, 
particularly in the local system, due to talks, research and genetic counselling. The number of tests 
performed may also have increased due to the development of direct mutation analysis for HD, and 
its implementation at the Division, making testing more easily available in Gauteng.  
 
4.5.2 Comparison between the two studies with regard to the utilization of the HD 
predictive testing service offered by the Division 
 
More HD predictive tests have been done per year between 1998 and 2006 (6.33 per year) than the 
number done per year between 1989 and 1997 (4.56 per year). Although the Kromberg et al. 
(1999) study looked at testing from 1975 to 1997, linkage analysis only became available in 1989. 
The increase in the number of HD predictive tests done may be due to the implementation of the 
predictive testing program, as well as the development and availability of direct mutation testing 
for HD. This would eliminate the need for extensive family study, and would provide a more 
definitive result than linkage analysis. A Scottish study also showed an increase in the number of 
HD predictive tests requested following the development of direct mutation testing for HD, and the 
researchers suggested that this was due to the definitive results obtained by this method (Holloway, 
Porteous, Fitzpatrick et al. 1998). Awareness of the HD predictive testing program may also have 
increased, perhaps from outreach projects, such as presentations to professionals, or by word of 
mouth within families. 
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4.5.3 Comparison between the two studies with regard to the utilization of the HD prenatal 
testing service offered by the Division 
 
The number of HD prenatal tests done per year has remained low, with 1.11 tests being done per 
year between 1989 and 1997 and one being done per year between 1998 and 2006. The lack of an 
increase in the number of HD prenatal tests performed over time may suggest a continuing lack of 
awareness of the service, most probably by individuals who have tested positive for HD 
diagnostically rather than those who completed the HD predictive testing process. There may also 
perhaps be a lack of interest in the service. The reasons for possible lack of interest in the service 
have been discussed in section 4.1.4.  
 
Decisions taken after a positive HD result have remained consistent, with all couples choosing to 
terminate the pregnancy. Direct mutation testing has replaced linkage analysis, as this test is more 
definitive. Similar findings with regard to terminating affected pregnancies, and a shift towards 
direct mutation testing, have been shown in other studies (Reviewed in Richards and Rea, 2005)   
 
4.6 LIMITATIONS OF THE STUDY DESIGN AND DATA COLLECTION 
 
A limitation of this study included lack of information such as missing files or missing information 
in files. Information used in this study was obtained from patient records from the Division and 
relied on information written by genetic counsellors and clinicians, as well as laboratory test 
results. One area where this may have been a major limitation is with regard to patients’ 
motivations for entering the HD predictive testing program. Many individuals may have given 
“planning for the future” as their reason for requesting HD predictive testing, which would have 
been written into the file, but what they meant by this may not have been fully documented (for 
example, financial planning, aiding in reproductive decision-making, planning relationships, 
careers and employment).          
 
Missing information in files may have resulted in inaccurate reflections about the cohort of HD 
diagnostic patients. Missing information included ages, ethnicity, number of children, relationship 
status, employment status and gender, which was often not reported in the files of HD diagnostic 
patients.  
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4.7 RECOMMENDATIONS  
 
From the results of this study, it appears that there has been an increase in the number of 
individuals requesting HD predictive testing, as well as an increase in the number of HD diagnostic 
tests being performed. The service still seems to be under-utilised, though. It is recommended that 
the current service be continued, but that provisions are made for an increasing number of 
individuals who may start utilising this service. This may include training more genetic counsellors 
to offer predictive testing for HD, and increasing laboratory staff numbers over time to ensure that 
the HD diagnostic service continues to run smoothly.  
 
It is also important to continue with publicity awareness because it seems that there is still a lack of 
awareness of the services available. This can include giving talks to educate medical professionals 
about the indications for HD testing, and talking to doctors after their patients receive a positive 
HD result to encourage them to refer these patients for genetic counselling. Publicity awareness 
can also include providing information for family members of individuals with HD as well as 
involvement in HD support groups. One way in which patients are being educated about HD is by 
posting newsletters to affected patients with up-to-date HD information, which they can pass onto 
their families. Information can also be made available to the public to educate them about HD and 
inform them of the services offered, either by way of pamphlets or by hosting seminars.  
 
4.8 FUTURE RESEARCH 
 
Future research could include continuing this study into the future to assess and follow trends 
further over time. It may also be important to extend this study to include patients seen for HD 
diagnostic, predictive and prenatal testing in other areas of South Africa. The laboratories at the 
NHLS in Johannesburg and in Cape Town, process the majority of HD samples in South Africa. 
There are also private laboratories in South Africa which offer HD testing. Individuals tested by 
other laboratories in South Africa could be included in a study, and results of a broader study could 
give a better overview of HD in South Africa.  
 
Future research could include further studies into the prevalence of HD within the different ethnic 
groups, as well as reasons for any discrepancies found. It may also be interesting to look at the 
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motivations of South African individuals not to enter the HD predictive testing program, and 
reasons why individuals do not complete the process. Other areas of interest which could be 
researched include the number of individuals who decide to have children following a positive HD 
result, whether these individuals choose an alternative reproductive method such as adoption, 
egg/sperm donation or PGD, and how many individuals who do not choose alternative 
reproductive options have prenatal HD testing.  
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5 CONCLUSION 
 
 
The majority of HD tests done by the Division were diagnostic tests (77%), followed by predictive 
tests (20%), then prenatal tests (3%). One of the overall findings of this study is that there has been 
an increase in diagnostic and predictive testing for HD, with prenatal testing remaining 
consistently low. It is, therefore, necessary to ensure that there are adequate resources available 
and sufficient numbers of trained laboratory technicians, clinicians and genetic counsellors to cope 
with the increasing number of HD tests being requested.  
 
Another finding of this study was that all individuals who requested prenatal and predictive HD 
testing received genetic counselling, but only 27.6% of individuals who had HD diagnostic testing 
received genetic counselling. This study therefore highlights the need for education of affected and 
at-risk individuals and their families about HD and the creation of a greater awareness of the HD 
genetic counselling and testing services among professionals and the public.  
 
This study has also provided an insight into the characteristics and motivations of the individuals 
who had genetic counselling and/or testing for HD. Most individuals in the HD diagnostic testing 
group were between the ages of 40 and 59 years, while those in the HD predictive testing group 
were between 20 and 29 years of age. In the HD predictive testing group, most individuals were 
white, suggesting an increased awareness of the HD predictive testing service among at-risk 
individuals in this population group. In the HD diagnostic testing group, the black population was 
still under-represented compared to the white population but to a lesser extent than in the HD 
predictive testing group. The most common motivation given by individuals who requested 
predictive testing for HD was to “decrease uncertainty” followed by “planning for the future”. The 
information obtained from this study regarding patient characteristics may be helpful in future 
genetic counselling sessions, and in patient care.  
 
This study has also highlighted areas where more information is needed, for example, regarding 
the frequency of HD in different ethnic groups, the low uptake rate of HD prenatal testing and 
reasons for individuals not entering the HD predictive testing program. A lot of information has 
been generated from this study, and can be used as a starting point for future research.   
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APPENDIX B 
DATA COLLECTION SHEET 1 
 
 
SUBJECT CODE:                              . 
 
PREDICTIVE TESTING 
 
 
1. Date of Birth:                                                    . 
 
2. Gender:  
1. Female    2. Male   
 
3. Ethnicity:    
1. White    2. Black    3. Indian   4. Mixed Ancestry    5. Unknown   
 
4. Relationship status: 
1. Single         2. Divorced/Separated             
3. Widowed     4. Married/ in relationship   
5. Unknown/Uncertain   
 
5. Occupation Status: 
1. Employed    2. Unemployed  
 
6. Number of children: 
0   1   2    3  4   5   6   7 Unknown   
 
7. Date of first genetic counselling session:                                                      .     
     7.1 Age at time:                   . 
 
8. Date of entry into the predictive testing process:                                          .  
8.1 Age at time:                   . 
 
9. Date of result-giving session:                                                                        .    
   9.1 Age at time:                    .    9.2 Not applicable  
 
10. Test Result: 
 1.1 Positive HD1    1.2 Positive HD2              
2.   Negative           3.   Not tested/No result   
 
11. Motivation for undergoing testing:   
1. To decrease uncertainty                             2. To plan for the future      
3. To aid in reproductive decision-making         4. To inform children       
5. Other:                                                                                                                     .  
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APPENDIX B (Cont.) 
DATA COLLECTION SHEET 2 
 
 
SUBJECT CODE:                              . 
 
DIAGNOSTIC TESTING 
 
1. Date of Birth:                                                    . 
 
 
2. Gender:  
 1. Female    2. Male   
 
 
3. Ethnicity:    
1. White    2. Black    3. Indian   4. Mixed Ancestry    5. Unknown   
 
 
4. Relationship status: 
1. Single         2. Divorced/Separated             
3. Widowed     4. Married/ in relationship   
5. Unknown/Uncertain   
 
 
5. Occupation Status: 
1. Employed    2. Unemployed  
 
 
6. Number of children: 
0   1   2    3  4   5   6   7 Unknown   
 
 
7. Date of test:                                          .     
    7.1. Age at time of test:                   . 
 
 
8. Test Result: 
 1.1 Positive HD1    1.2 Positive HD2            
2. Negative             3. Not tested/No result   
 
 
8. Reasons for test not being completed (if applicable):   
1. Test cancelled by requesting doctor    2.  Test failed      
3. Incorrect collection tube used               
4. Other:                                                         .  
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APPENDIX B (Cont.) 
DATA COLLECTION SHEET 3 
 
 
SUBJECT CODE:                              . 
 
 
PRENATAL TESTING 
 
 
1. Gestational Age:                                                    . 
 
 
2. Gender of fetus:  
 1. Female    2. Male     3. Unknown  
 
 
3. Status of parent: 
1. Affected    2. At 50% risk       
 
 
4. Gender of affected/at risk parent:  
 1. Female    2. Male   
 
 
5. Age of affected parent at time of test:                           . 
 
 
6. Number of other children in the family: 
0   1   2    3  4   5   6   7 Unknown   
 
 
7. Test Result: 
 1.1 Positive HD1    1.2 Positive HD2            
2. Negative             3. Not tested/No result   
 
 
8. Number of CAG repeats:                          .   
 
 
9. Decision made following a positive result: 
1. Termination of pregnancy  2.  Continuation of pregnancy      
3. Not Known                         
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APPENDIX C 
Ethics Clearance Certificate  
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APPENDIX D 
Letter of appeal regarding ethics clearance conditions 
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APPENDIX E 
Table of characteristics of the individuals who completed the HD 
predictive testing program and those who did not 
 
 
 
Table summarising the characteristics of the individuals who requested predictive testing for HD 
between January 1998 and December 2006. The table also shows a comparison between the 
individuals who completed the predictive testing process and those who did not.  
 
 Total Completed  Not Completed  
Gender    
   Female 38             (66.7) 23 15 
   Male 19             (33.3) 15 4 
   p-value  p=0.21 (Not significant) 
    
Ethnicity    
   White 52             (91.2) 36 16 
   Black 2                 (3.5) 0 2 
   Indian 1                 (1.8) 0 1 
   Mixed Ancestry 2                 (3.5) 2 0 
   p-value  p=0.07 (not significant) 
 
   
Relationship Status    
   Not in relationship                    16             (28.1) 9 7 
   In a relationship/Married 40             (70.2) 29 11 
   Unknown 1                 (1.7) 0 1 
   p-value  p=0.34 (not significant) 
    
Employment Status    
   Employed 42             (73.7) 31 11 
   Not employed 13             (22.8)                           7 6 
   Unknown 2                 (3.5) 0 2 
   p-value  p=0.19 (not significant) 
    
Number of Children    
   0 children 31             (54.4) 21 10 
   1 or more children  25             (43.9) 17 8 
   Unknown 1                 (1.7) 0 1 
   p-value  p=1.0 (not significant) 
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Age   
   Under 20 3                 (5.3) 2 1 
   20-29 24             (42.1)  14 10 
   30-39 20             (35.1)  16 4 
   40-49 6               (10.5) 4 2 
   Over 50 4                 (7.0)  2 2 
   p-value  p=0.53 (not significant) 
 
 
